[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2455
1. Sun B, Li S, Yang L, Damodaran T, Desai D, Diehl AM, Alzate O, Koeberl DD: Activation of glycolysis and apoptosis in glycogen storage disease type Ia. Mol Genet Metab; 2009 Aug;97(4):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of glycolysis and apoptosis in glycogen storage disease type Ia.
  • The deficiency of glucose-6-phosphatase (G6Pase) underlies glycogen storage disease type Ia (GSD-Ia, von Gierke disease; MIM 232200), an autosomal recessive disorder of metabolism associated with life-threatening hypoglycemia, growth retardation, renal failure, hepatic adenomas, and hepatocellular carcinoma.
  • Liver involvement includes the massive accumulation of glycogen and lipids due to accumulated glucose-6-phosphate and glycolytic intermediates.
  • Proteomic analysis revealed elevations in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and other enzymes involved in glycolysis.
  • The moonlighting role of GAPDH includes increasing apoptosis, which was demonstrated by increased TUNEL assay positivity and caspase 3 activation in the murine GSD-Ia liver.
  • These analyses of hepatic involvement in GSD-Ia mice have implicated the induction of apoptosis in the pathobiology of GSD-Ia.
  • [MeSH-major] Apoptosis / genetics. Glycogen Storage Disease Type I / physiopathology. Glycolysis / genetics
  • [MeSH-minor] Animals. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Liver / pathology. Mice

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419892.001).
  • [ISSN] 1096-7206
  • [Journal-full-title] Molecular genetics and metabolism
  • [ISO-abbreviation] Mol. Genet. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


2. Abdel-Hamid MK, Abdel-Hafez AA, El-Koussi NA, Mahfouz NM, Innocenti A, Supuran CT: Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity. Bioorg Med Chem; 2007 Nov 15;15(22):6975-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new series of 1,3,4-thiadiazole-2-thione derivatives have been prepared and assayed for the inhibition of three physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isozymes, the cytosolic human isozymes I and II, and the transmembrane, tumor-associated hCA IX.
  • Against hCA I the investigated thiones, showed inhibition constants in the range of 2.55-222 microM, against hCA II in the range of 2.0-433 microM, and against hCA IX in the range of 1.25-148 microM.
  • Compound 5c, 4-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-1-(5-nitro-2-oxoindolin-3-ylidene)semicarbazide showed interesting inhibition of the tumor-associated hCA IX with K(I) value of 1.25 microM, being the first non-sulfonamide type inhibitor of such activity.

  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822907.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,3,4-thiadiazole-2-thione; 0 / Carbonic Anhydrase Inhibitors; 0 / Ligands; 0 / Thiadiazoles; 0 / Thiones; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.- / Carbonic Anhydrase IV
  •  go-up   go-down


3. Fisher SZ, Tu C, Bhatt D, Govindasamy L, Agbandje-McKenna M, McKenna R, Silverman DN: Speeding up proton transfer in a fast enzyme: kinetic and crystallographic studies on the effect of hydrophobic amino acid substitutions in the active site of human carbonic anhydrase II. Biochemistry; 2007 Mar 27;46(12):3803-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catalysis of the hydration of CO2 by human carbonic anhydrase isozyme II (HCA II) is sustained at a maximal catalytic turnover of 1 mus-1 by proton transfer between a zinc-bound solvent and bulk solution.
  • Correlating these structural variants with kinetic studies suggests that the very efficient proton transfer (approximately 7 micros-1) observed for Y7F HCA II in the dehydration direction, compared with the wild type and other mutants of this study, is due to a combination of three features.
  • Second, in the structure of Y7F HCA II, there is an unbranched chain of hydrogen-bonded waters linking the proton donor His64 and acceptor zinc-bound hydroxide.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330962.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM25154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 059QF0KO0R / Water; 142M471B3J / Carbon Dioxide; 4QD397987E / Histidine; EC 4.2.1.- / Carbonic Anhydrase II
  •  go-up   go-down


Advertisement
4. Hoban V: HCAs in nursing: what role should they play? Nurs Times; 2008 May 20-26;104(20):18-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCAs in nursing: what role should they play?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546986.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Ayhan S, Isisag A, Saruc M, Nese N, Demir MA, Kucukmetin NT: The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology; 2010 Mar-Apr;57(98):251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This study is aimed to investigate abnormal expression of the Rb protein (pRb), p16(INK4a) (p16) and cyclin D1 in colorectal adenomas and adenocarcinomas and to assess the possible alterations in Rb pathway in colorectal carcinogenesis.
  • METHODOLOGY: 44 cases of colorectal adenoma and 44 cases of colorectal adenocarcinoma were examined histopathologically and immunohistochemically using monoclonal antibodies to identify abnormalities of pRb, p16, and cyclin D1 expression.
  • RESULTS: In 70.5% of the adenomas and 97.7% of the adenocarcinomas, an overexpression of pRb was found.
  • There was a statistically significant relationship between the immunoreactivity of pRb and villous/tubulovillous types of adenomas (p < 0.05).
  • There was a loss of p16 expression in 84.1% of adenomas and 61.4% of adenocarcinomas.
  • Statistically significantly, the p16 overexpression was not seen in any of tubular adenomas (p < 0.001).
  • Overexpression of cyclin D1 was found in only 9.1% of adenomas, while 31.8% of adenocarcinomas overexpressed this protein.
  • Loss of expression of cyclin D1 was similar in adenomas and adenocarcinomas (27.3% and 25%, respectively).
  • Staining degrees of all three cell cycle proteins were shown to be statistically different in adenomas and adenocarcinomas, for pRb (p = 0.001), for p16 ( p = 0.045), and cyclin D1 ( p = 0.05).
  • Also, there was only a mild agreement with respect to p16 and cyclin D1 relationship between for adenomas ( K = +0.28 p = 0.051) and for adenocarcinomas ( K = +0.35 p = 0.017).
  • Besides, there was no correlation between the expression of pRb, p16, and cyclin D1 and clinicopathological tumor characteristics and prognostic data such as stage or lymph node/liver metastasis.
  • CONCLUSIONS: pRb, p16 and cyclin D1 are shown to be aberrantly expressed in both colorectal adenomas and adenocarcinomas.
  • It can be claimed that disturbances in Rb pathway take part in colonic carcinogenesis and pRb, p16 and cyclin D1 play an ever increasing role in the further stages of adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Chi-Square Distribution. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged


6. Ali K, Lu Y, Christensen C, May T, Hyett C, Griebel R, Fourney D, Meguro K, Resch L, Sharma RK: Fourier transform infrared spectromicroscopy and hierarchical cluster analysis of human meningiomas. Int J Mol Med; 2008 Mar;21(3):297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fourier transform infrared spectromicroscopy and hierarchical cluster analysis of human meningiomas.
  • Limitations of conventional light microscopy in pathological diagnosis of brain tumors include subjective bias in interpretation and discordance of nomenclature.
  • Spectral datasets were subjected to hierarchical cluster analyses (HCA) using Ward's algorithm for comparison and grouping of similar data groups, and were converted into color-coded digital maps for matching spectra with their respective clusters.
  • False color images of 5 and 6 clusters obtained by HCA identified dominant clusters corresponding to tumor tissue.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology
  • [MeSH-minor] Aged. Cluster Analysis. Female. Humans. Male. Middle Aged. Spectroscopy, Fourier Transform Infrared

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288376.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


7. Guo W, He MC, Yang ZF, Lin CY, Quan XC: Occurrence of aliphatic hydrocarbons in water, suspended particulate matter and sediments of Daliao River system, China. Bull Environ Contam Toxicol; 2010 May;84(5):519-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hierarchical cluster analysis (HCA) of aliphatic hydrocarbons is correspondence with hydrocarbons indexes results.
  • [MeSH-major] Air Pollutants / analysis. Alkanes / analysis. Geologic Sediments / chemistry. Industrial Waste / analysis. Particulate Matter / analysis. Rivers / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20411239.001).
  • [ISSN] 1432-0800
  • [Journal-full-title] Bulletin of environmental contamination and toxicology
  • [ISO-abbreviation] Bull Environ Contam Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Alkanes; 0 / Industrial Waste; 0 / Particulate Matter
  •  go-up   go-down


8. Saito M, Ueno M, Ogino S, Kubo K, Nagata J, Takeuchi M: High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. Food Chem Toxicol; 2005 Mar;43(3):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the ability of Garcinia cambogia extract containing (-)-hydroxycitric acid (HCA) to suppress body fat accumulation in developing male Zucker obese (fa/fa) rats.
  • Diets containing different levels of HCA (0, 10, 51, 102 and 154 mmol/kg diet) were fed to 6-week-old rats for 92 or 93 days.
  • Each diet group was pair-fed to the 154 mmol HCA/kg diet group.
  • The highest dose of HCA-containing Garcinia cambogia (154 mmol HCA/kg diet) showed significant suppression of epididymal fat accumulation in developing male Zucker obese rats, compared with the other groups.
  • However, the diets containing 102 mmol HCA/kg diet and higher (778 and 1244 mg HCA/kg BW/d, respectively) caused potent testicular atrophy and toxicity, whereas diets containing 51 mmol HCA/kg diet (389 mg HCA/kg BW/d) or less did not.
  • Accordingly, 51 mmol HCA/kg diet (389 mg HCA/kg BW/d) was deemed to be the no observed adverse effect level (NOAEL).
  • [MeSH-minor] ATP Citrate (pro-S)-Lyase / metabolism. Animals. Anti-Obesity Agents / toxicity. Dose-Response Relationship, Drug. Leptin / blood. Liver / drug effects. Liver / enzymology. Liver / metabolism. Male. No-Observed-Adverse-Effect Level. Organ Size / drug effects. Random Allocation. Rats. Rats, Zucker. Testosterone / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Food Chem Toxicol. 2005 Nov;43(11):1683-4; author reply 1685-6 [15993998.001]
  • (PMID = 15680676.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Citrates; 0 / Leptin; 0 / Plant Extracts; 3XMK78S47O / Testosterone; 8W94T9026R / hydroxycitric acid; EC 2.3.3.8 / ATP Citrate (pro-S)-Lyase
  •  go-up   go-down


9. Kühnel D, Taugner F, Scholtka B, Steinberg P: Inflammation does not precede or accompany the induction of preneoplastic lesions in the colon of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-fed rats. Arch Toxicol; 2009 Aug;83(8):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterocyclic aromatic amines (HCAs) are formed in meat cooked at high temperatures for a long time or over an open flame.
  • In this context 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the most abundant HCA in cooked meat, has been suggested to be involved in colon and prostate carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212758.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-amino-1-methyl-6-phenyl-1H-imidazo(4,5-b)pyridine; 0 / Aminopyridines; 0 / Carcinogens; 0 / Imidazoles
  •  go-up   go-down


10. Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, Guillemette C: UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res; 2008 Sep 26;644(1-2):56-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucuronidation by the UDP-glucuronosyltransferase enzymes (UGTs) is one of the primary detoxification pathways of dietary heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs).
  • In a population-based case-control study of 537 cases and 866 controls, we investigated whether colon cancer was associated with genetic variations in UGT1A1 and UGT1A9 genes and we determined if those variations modify the association between colon cancer and dietary HCA and PAH exposure.
  • This finding is also supported by haplotype analyses where the UGT1A1-3279G-allele-bearing haplotype is overrepresented in case group.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1994 May 12;369(6476):154-6 [7909916.001]
  • [Cites] Carcinogenesis. 1994 Aug;15(8):1711-6 [8055653.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6154-9 [7954461.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):525-9 [7834621.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):61-4 [7612905.001]
  • [Cites] N Engl J Med. 1995 Nov 2;333(18):1171-5 [7565971.001]
  • [Cites] Epidemiology. 1995 Jul;6(4):455-7 [7548362.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Mutat Res. 1997 May 12;376(1-2):195-202 [9202756.001]
  • [Cites] Biochim Biophys Acta. 1998 Jul 1;1407(1):40-50 [9639672.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2407-15 [15319294.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):185-91 [15643497.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):457-60 [15770010.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):295-301 [15864130.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3250-4 [15929176.001]
  • [Cites] Chem Res Toxicol. 2004 Aug;17(8):1137-44 [15310245.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1629-37 [15090468.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Environ Health Perspect. 1986 Aug;67:17-24 [3757953.001]
  • [Cites] Environ Health Perspect. 1986 Aug;67:5-10 [3530738.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3367-76 [2334931.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):251-61 [2017211.001]
  • [Cites] Am J Epidemiol. 1991 Aug 15;134(4):421-32 [1877602.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jun 30;185(3):839-44 [1627140.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1626-32 [16030093.001]
  • [Cites] Hepatology. 2005 Aug;42(2):448-57 [15986396.001]
  • [Cites] Pharmacogenet Genomics. 2005 Oct;15(10):713-21 [16141797.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):2019-28 [15944213.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):943-9 [16510539.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jun;21(6):1036-41 [16724991.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):717 [16786511.001]
  • [Cites] Clin Pharmacol Ther. 2007 Mar;81(3):392-400 [17339869.001]
  • [Cites] Mutat Res. 2008 Feb 1;638(1-2):162-74 [18022202.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):950-6 [10706110.001]
  • [Cites] Pharm Res. 2000 Jan;17(1):21-6 [10714603.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6921-6 [11156391.001]
  • [Cites] Food Chem Toxicol. 2001 May;39(5):423-36 [11313108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):439-46 [11352852.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):943-50 [11375903.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1978-86 [11929814.001]
  • [Cites] Drug Metab Rev. 2002 Aug;34(3):625-50 [12214671.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:197-204 [12351159.001]
  • [Cites] Pharmacogenetics. 2002 Dec;12(9):725-33 [12464801.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1611-21 [12496052.001]
  • [Cites] Am J Epidemiol. 2003 Mar 1;157(5):434-45 [12615608.001]
  • [Cites] Genet Epidemiol. 2003 Sep;25(2):115-21 [12916020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):747-54 [12917206.001]
  • [Cites] Am J Epidemiol. 2003 Nov 15;158(10):951-62 [14607803.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):102-9 [14744740.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1382-8 [15007088.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):44-55 [15199546.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):501-15 [15284532.001]
  • (PMID = 18675828.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / R01 CA66635; United States / NCI NIH HHS / CA / R01 CA066635; United States / NICHD NIH HHS / HD / K12 HD051958; United States / NIDDK NIH HHS / DK / P30 DK034987-23; United States / NICHD NIH HHS / HD / 5K12HD051958; United States / NCI NIH HHS / CA / R01 CA066635-09; United States / NIDDK NIH HHS / DK / P30 DK34987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Heterocyclic Compounds; 0 / Polycyclic Hydrocarbons, Aromatic; EC 2.4.1.- / UGT1A1 enzyme; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.17 / UDP-glucuronosyltransferase 1A9
  • [Other-IDs] NLM/ NIHMS66700; NLM/ PMC2570038
  •  go-up   go-down


11. Wong MA, Hopkins AL, Meeks JC, Clarke JD: Evaluation of treatment with a combination of azathioprine and prednisone in dogs with meningoencephalomyelitis of undetermined etiology: 40 cases (2000-2007). J Am Vet Med Assoc; 2010 Oct 15;237(8):929-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common adverse effects included weight gain, thinning of the hair, and elevated activities of liver enzymes, all of which may have been attributed to concurrent corticosteroid administration.
  • Less common adverse effects included diabetes mellitus, keratoconjunctivitis sicca, mammary gland adenoma, lymphoma, and hepatic masses.

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20946080.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N: Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci; 2007 Mar;98(3):321-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.
  • We previously observed that Pim-3 with serine/threonine kinase activity, was aberrantly expressed in malignant lesions of endoderm-derived organs, liver and pancreas.
  • Moreover, Pim-3 proteins were detected in adenoma (35/40 cases) and normal mucosa (26/111 cases), which are adjacent to adenocarcinoma.
  • Pim-3 was constitutively expressed in SW480 cells and the transfection with Pim-3 short hairpin RNA promoted apoptosis.
  • In the same cell line, a pro-apoptotic molecule, Bad, was phosphorylated at Ser(112) and Ser(136) sites of phosphorylation that are representative of its inactive form.
  • Ser(112) but not Ser(136) phosphorylation in this cell line was abrogated by Pim-3 knockdown.
  • These observations suggest that Pim-3 can inactivate Bad by phosphorylating its Ser(112) in human colon cancer cells and thus may prevent apoptosis and promote progression of human colon cancer.
  • [MeSH-minor] Apoptosis / physiology. Cell Line, Tumor. Female. HCT116 Cells. HT29 Cells. Humans. Immunohistochemistry. Male

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270021.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / bcl-Associated Death Protein; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


13. Chung YW, Han DS, Park YK, Son BK, Paik CH, Lee HL, Jeon YC, Sohn JH: Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis; 2006 Sep;38(9):668-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea.
  • This case-control study was conducted to investigate the association between obesity, serum lipids and glucose, and the risk of advanced colorectal adenoma and cancer.
  • METHODS: Patients with histologically confirmed colorectal cancers (n=105), same number of patients with advanced colorectal adenomas matched by age and sex, and the same number of controls matched by age and sex were selected in Hanyang University Guri Hospital between January 2002 and June 2004.
  • RESULTS: Adenoma and cancer group showed significantly higher levels of mean body mass index and serum glucose.
  • We used an unordered polytomous logistic model to calculate multivariate odds ratios for advanced adenoma and cancer relative to controls.
  • Higher serum glucose level was more strongly associated with increased risk of cancer relative to controls (odds ratio, 3.0; 95% confidence interval, 0.9-9.8) than with increased risk of advanced adenoma (odds ratio, 2.1; 95% confidence interval, 0.9-5.4).
  • Higher body mass index was strongly associated with increased risk of advanced adenoma (odds ratio, 10.8; 95% confidence interval, 4.6-25.3), but associated with attenuated risk of cancer (odds ratio, 2.3; 95% confidence interval, 0.9-5.8).
  • CONCLUSIONS: Obesity and hyperglycaemia are positively related to advanced colorectal adenoma formation.
  • [MeSH-major] Adenomatous Polyps / blood. Adenomatous Polyps / complications. Blood Glucose / analysis. Colorectal Neoplasms / blood. Colorectal Neoplasms / complications. Lipids / blood. Obesity / complications
  • [MeSH-minor] Body Mass Index. Case-Control Studies. Female. Humans. Hyperglycemia / blood. Korea. Male. Middle Aged. Multivariate Analysis. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790371.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Lipids
  •  go-up   go-down


14. Defrain C, Chang CY, Srikureja W, Nguyen PT, Gu M: Cytologic features and diagnostic pitfalls of primary ampullary tumors by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer; 2005 Oct 25;105(5):289-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-guided FNAB) is highly sensitive and specific in cytologic diagnosis and clinical staging of malignant neoplasms of the gastrointestinal tract, pancreas, liver, and lymph nodes.
  • The number of passes necessary to arrive at a preliminary diagnosis during adequacy assessment was documented.
  • Atypical cells were found in six patients, four of which were suspicious for adenocarcinoma and two of which were consistent with reactive atypia.
  • Adenoma was diagnosed in two patients and carcinoid tumor in one.
  • Thirteen patients had a diagnosis that was negative for malignant cells.
  • The consistent cytologic features in specimens that were positive or suspicious for adenocarcinoma included high cellularity, single cells, 3-dimensional cell balls, high nuclear-to-cytoplasmic ratio, prominent nucleoli, coarse/uneven distribution of chromatin, and necrosis.
  • Adenoma presented a diagnostic challenge and endosonographic correlation was instrumental to increase the diagnostic accuracy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986397.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bitencourt Fda S, Figueiredo JG, Mota MR, Bezerra CC, Silvestre PP, Vale MR, Nascimento KS, Sampaio AH, Nagano CS, Saker-Sampaio S, Farias WR, Cavada BS, Assreuy AM, de Alencar NM: Antinociceptive and anti-inflammatory effects of a mucin-binding agglutinin isolated from the red marine alga Hypnea cervicornis. Naunyn Schmiedebergs Arch Pharmacol; 2008 Apr;377(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The agglutinin from the red marine alga Hypnea cervicornis (HCA) was tested in models of nociception and inflammation.
  • HCA (10(-1), 1, and 10 mg/kg) administered i.v. to mice inhibited writhes induced by acetic acid and, at 10 mg/kg, inhibited the second phase of the formalin test, but did not alter the response latency in the hot-plate test.
  • HCA (1 mg/kg) administered i.v. to rats reduced carrageenan-induced paw edema at 1, 2, and 3 h after challenge, but not edema induced by dextran.
  • The neutrophil migration induced by both N-formyl-methionyl-leucyl-phenylalanine (fMLP) and carrageenan was inhibited by HCA at 10(-1), 1, and 10 mg/kg.
  • The combination of HCA (1 mg/kg) and its ligand mucin reversed the lectin inhibitory effect on carrageenan-induced neutrophil migration and acetic acid-induced writhes.
  • The i.v. treatment of rats with HCA (1 mg/kg) for 7 days did not affect body mass; liver, kidney or heart wet weight; blood leukocyte counts; urea, creatinine or serum transaminase activity; or macroscopy of the organs examined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Pept Lett. 2004 Apr;11(2):195-200 [15078209.001]
  • [Cites] Pain. 1989 Sep;38(3):347-52 [2478947.001]
  • [Cites] Br J Pharmacol. 1999 Feb;126(3):537-50 [10188959.001]
  • [Cites] Science. 1984 Aug 17;225(4663):743-5 [6087456.001]
  • [Cites] Fitoterapia. 2001 Feb;72(2):131-9 [11223222.001]
  • [Cites] Biochem Cell Biol. 2006 Feb;84(1):49-54 [16462889.001]
  • [Cites] Immunol Rev. 2002 Aug;186:8-18 [12234358.001]
  • [Cites] J Pharm Pharmacol. 2005 Mar;57(3):375-81 [15807994.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Jan;112(1):27-35 [8980461.001]
  • [Cites] Int Immunopharmacol. 2007 Jun;7(6):824-35 [17466916.001]
  • [Cites] Prog Neurobiol. 2001 Jul;64(4):327-63 [11275357.001]
  • [Cites] FASEB J. 1995 Jul;9(10):866-73 [7542213.001]
  • [Cites] Gut. 1994 Jul;35(7):909-15 [8063218.001]
  • [Cites] Neuropharmacology. 1985 Aug;24(8):729-34 [3841806.001]
  • [Cites] Anesth Analg. 2001 Jul;93(1):197-203 [11429365.001]
  • [Cites] Agents Actions. 1988 Jul;24(3-4):377-80 [3051931.001]
  • [Cites] Biochem Cell Biol. 2005 Oct;83(5):659-66 [16234855.001]
  • [Cites] Br J Pharmacol. 1995 Mar;114(5):1069-75 [7780642.001]
  • [Cites] J Pharm Pharmacol. 1979 Sep;31(9):648 [41077.001]
  • [Cites] Brain Res. 1998 Mar 16;787(1):161-4 [9518591.001]
  • [Cites] J Ethnopharmacol. 2001 Dec;78(2-3):151-7 [11694360.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1990 Apr;38(4):1045-8 [2379278.001]
  • [Cites] Br J Pharmacol. 1995 Feb;114(3):578-83 [7537590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 [15665080.001]
  • [Cites] Glycoconj J. 1995 Feb;12(1):1-6 [7795408.001]
  • [Cites] J Agric Food Chem. 2002 Jun 19;50(13):3862-6 [12059172.001]
  • [Cites] Pain. 1992 Oct;51(1):5-17 [1454405.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):1-10 [16957941.001]
  • [Cites] Plant Physiol. 1995 Oct;109(2):347-52 [7480335.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Aug;310(2):710-7 [15075358.001]
  • [Cites] Pak J Pharm Sci. 1993 Jan;6(1):45-51 [16414726.001]
  • [Cites] Braz J Med Biol Res. 2007 Jan;40(1):127-34 [17225005.001]
  • [Cites] J Pharm Pharmacol. 2005 Jul;57(7):919-22 [15969953.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):1050-5 [17045568.001]
  • [Cites] Agents Actions. 1993 Jan;38(1-2):48-54 [8480538.001]
  • [Cites] Braz J Med Biol Res. 2004 Jul;37(7):1071-9 [15264015.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2007 Jan;374(4):275-82 [17171556.001]
  • [Cites] Mediators Inflamm. 1999;8(2):107-13 [10704148.001]
  • [Cites] Inflamm Res. 2001 Oct;50(10):486-90 [11713900.001]
  • [Cites] J Ethnopharmacol. 1996 Sep;53(3):175-8 [8887026.001]
  • [Cites] Mediators Inflamm. 1997;6(3):201-10 [18472821.001]
  • [Cites] Life Sci. 2001 Nov 2;69(24):2911-9 [11720094.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Dec;35(12):1674-81 [12962707.001]
  • [Cites] J Pharmacol Exp Ther. 1982 Apr;221(1):261-7 [6174730.001]
  • [Cites] Agents Actions. 1985 Oct;17(1):97-103 [4083185.001]
  • [Cites] Protein Sci. 2005 Aug;14(8):2167-76 [16046632.001]
  • [Cites] Br J Pharmacol. 2006 Sep;149(1):14-22 [16865092.001]
  • [Cites] J Pharmacol Exp Ther. 1953 Mar;107(3):385-93 [13035677.001]
  • [Cites] J Urol. 1999 Jun;161(6):1988-93 [10332487.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1805-14 [15914076.001]
  • [Cites] Neuropeptides. 1997 Aug;31(4):381-9 [9308027.001]
  • [Cites] Phytother Res. 2001 May;15(3):224-30 [11351357.001]
  • [Cites] Eur J Pharmacol. 2000 Jan 3;387(1):111-8 [10633169.001]
  • [Cites] Braz J Med Biol Res. 2002 Jun;35(6):713-22 [12045837.001]
  • [Cites] Br J Pharmacol. 1996 Feb;117(3):552-558 [8821548.001]
  • (PMID = 18270688.001).
  • [ISSN] 0028-1298
  • [Journal-full-title] Naunyn-Schmiedeberg's archives of pharmacology
  • [ISO-abbreviation] Naunyn Schmiedebergs Arch. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Agglutinins; 0 / Analgesics; 0 / Anti-Inflammatory Agents; 0 / Lectins; 0 / Mucins
  •  go-up   go-down


16. Galloro V: HCA scores on bond market. First-quarter earnings expected to top $600 million. Mod Healthc; 2009 Apr 20;39(16):12-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA scores on bond market. First-quarter earnings expected to top $600 million.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422133.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


17. Heppner CW, Schlatter JR: Data requirements for risk assessment of furan in food. Food Addit Contam; 2007;24 Suppl 1:114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furan is carcinogenic in rats and mice, showing a dose-dependent increase in hepatocellular adenomas and carcinomas.
  • In rats, a dose-dependent increase of mononuclear leukaemia is evident and a very high incidence of cholangiocarcinomas of the liver, even at the lowest dose tested.
  • However, chronic toxicity with secondary cell proliferation may indirectly amplify the tumour response.
  • [MeSH-major] Carcinogens, Environmental / analysis. Food Contamination / analysis. Furans / analysis
  • [MeSH-minor] Animals. DNA / drug effects. DNA / genetics. Food Analysis / methods. Gas Chromatography-Mass Spectrometry / methods. Humans. Mice. Mutagenesis / drug effects. Neoplasms, Experimental / chemically induced. Proto-Oncogenes / drug effects. Proto-Oncogenes / genetics. Rats. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • Hazardous Substances Data Bank. Furan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687705.001).
  • [ISSN] 0265-203X
  • [Journal-full-title] Food additives and contaminants
  • [ISO-abbreviation] Food Addit Contam
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Furans; 9007-49-2 / DNA; UC0XV6A8N9 / furan
  • [Number-of-references] 34
  •  go-up   go-down


18. Al Awad-Jibara A, Chirinos Vargas JR, Baena SJ, Pirela-Finol CA, Brea-Andrade AF, Yajure-Perozo ME: [Laparoscopic hepatectomy in benign solid tumor: case report]. Cir Cir; 2009 May-Jun;77(3):223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic hepatectomy in benign solid tumor: case report].
  • [Transliterated title] Hepatectomía laparoscópica en tumor sólido benigno. Informe de un caso.
  • BACKGROUND: Laparoscopic liver surgery represents an alternative surgical approach in the presence of smaller solid tumors up to 5 cm located in the left lobe and in anterior segments of the right lobe.
  • The objective of this report is to present the first hepatic resection by laparoscopy, reported in Venezuela, as well as also the review in the literature.
  • CLINICAL CASE: A 40-year-old female was referred to the Surgical Service of the Hospital Universitario de Maracaibo for mild epigastric pain of 1-year evolution, in addition to having a palpable mass in the same region; laboratory tests and tumor markers was normal.
  • Complementary studies such as computed abdominal tomography and ultrasound revealed a lesion of 5.8 x 4.3 cm, localized in segments II and III of the liver.
  • The liver segment was resected through a transverse suprapubic incision.
  • Final pathological report demonstrated hepatocellular adenoma.
  • CONCLUSIONS: Laparoscopic approach is another alternative in the surgical management of solid liver lesions.
  • [MeSH-major] Adenoma, Liver Cell / surgery. Hepatectomy / methods. Laparoscopy. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671275.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 22
  •  go-up   go-down


19. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, Watanabe M: Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol; 2010 May;45(5):523-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
  • Here, we screened host genes and molecular pathways that are involved in HCV replication by comprehensive analyses using two genotypes of HCV replicon-expressing cells, their cured cells and naïve Huh7 cells.
  • METHODS: Huh7 cell lines that stably expressed HCV genotype 1b or 2a replicon were used.
  • The cured cells were established by treating HCV replicon cells with interferon-alpha.
  • RESULTS: Hierarchical clustering analysis showed that the gene-expression profiles of each cell group constituted clear clusters of naïve, HCV replicon-expressed, and cured cell lines.
  • The pathway process analysis between the replicon-expressing and the cured cell lines identified significantly altered pathways, including MAPK, steroid biosynthesis and TGF-beta signaling pathways, suggesting that these pathways were affected directly by HCV replication.
  • Comparison of cured and naïve Huh7 cells identified pathways, including steroid biosynthesis and sphingolipid metabolism, suggesting that these pathways were required for efficient HCV replication.
  • Cytoplasmic lipid droplets were obviously increased in replicon-expressing and cured cells as compared to naïve cells.
  • CONCLUSION: Comprehensive gene expression and pathway analyses show that lipid biosynthesis pathways are crucial to support proficient virus replication.
  • [MeSH-minor] Cell Culture Techniques. Cell Line. Cluster Analysis. Gene Expression Profiling. Humans. Lipid Metabolism / physiology. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Mol Biol. 2007 May 22;8:38 [17519006.001]
  • [Cites] Mol Pharmacol. 2008 Oct;74(4):952-63 [18599600.001]
  • [Cites] J Gastroenterol. 2006 Aug;41(8):750-7 [16988763.001]
  • [Cites] Hepatology. 2008 Nov;48(5):1396-403 [18830996.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 28;318(2):514-9 [15120631.001]
  • [Cites] Ann Intern Med. 2004 Mar 2;140(5):346-55 [14996676.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2986-91 [15710892.001]
  • [Cites] J Viral Hepat. 2006 Oct;13(10):690-700 [16970601.001]
  • [Cites] DNA Cell Biol. 2000 Feb;19(2):113-20 [10701777.001]
  • [Cites] Virology. 2005 Jan 20;331(2):407-17 [15629783.001]
  • [Cites] Virology. 2008 Feb 5;371(1):71-85 [17949770.001]
  • [Cites] J Virol. 2004 Feb;78(3):1513-24 [14722306.001]
  • [Cites] J Gastroenterol. 2009;44(7):643-9 [19455277.001]
  • [Cites] Cell Host Microbe. 2009 Mar 19;5(3):298-307 [19286138.001]
  • [Cites] Science. 1999 Jul 2;285(5424):110-3 [10390360.001]
  • [Cites] Virology. 2002 Feb 1;293(1):31-43 [11853397.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):311-20 [17241881.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 1;357(2):467-73 [17433261.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Virology. 2005 May 10;335(2):264-75 [15840525.001]
  • [Cites] Nat Chem Biol. 2005 Nov;1(6):333-7 [16408072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9 [15939869.001]
  • [Cites] EMBO J. 2006 Oct 18;25(20):5015-25 [17024179.001]
  • [Cites] J Clin Invest. 1999 Jun;103(11):1489-98 [10359558.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 2;313(1):42-7 [14672695.001]
  • [Cites] EMBO Rep. 2003 Jun;4(6):602-8 [12740604.001]
  • [Cites] FEBS Lett. 2009 Sep 3;583(17 ):2720-6 [19631645.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1808-17 [14724833.001]
  • [Cites] J Virol. 2003 May;77(9):5487-92 [12692249.001]
  • [Cites] Virus Res. 2005 Jan;107(1):73-81 [15567036.001]
  • [Cites] J Infect Dis. 2004 Apr 1;189(7):1129-39 [15031779.001]
  • [Cites] J Infect Dis. 2008 Feb 1;197(3):361-70 [18248300.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S [9305666.001]
  • [Cites] FEBS Lett. 2006 Aug 7;580(18):4392-400 [16844119.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1027-41 [11297677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Virol. 2001 Sep;75(18):8516-23 [11507197.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29577-85 [9792666.001]
  • [Cites] Nat Med. 2005 Jul;11(7):791-6 [15951748.001]
  • [Cites] J Virol. 2002 Aug;76(15):7453-9 [12097557.001]
  • [Cites] Hepatology. 2006 Jul;44(1):117-25 [16799963.001]
  • [Cites] BMC Genomics. 2008 Jun 30;9:309 [18590516.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1383-9 [18410471.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1031-41 [16143140.001]
  • [Cites] J Virol. 2006 Apr;80(7):3332-40 [16537600.001]
  • [Cites] J Virol. 2002 Dec;76(24):13001-14 [12438626.001]
  • (PMID = 20012654.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


20. Mi J, Apraiz I, Cristobal S: Peroxisomal proteomic approach for protein profiling in blue mussels (Mytilus edulis) exposed to crude oil. Biomarkers; 2007 Jan-Feb;12(1):47-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hierarchical clustering analysis succeeded in discriminating the exposed groups from the control groups based on the unique PES.
  • [MeSH-major] Bivalvia / chemistry. Peroxisomes / drug effects. Petroleum / toxicity. Proteins / analysis. Proteomics. Water Pollutants, Chemical / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438653.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Petroleum; 0 / Proteins; 0 / Water Pollutants, Chemical
  •  go-up   go-down


21. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD: Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med; 2006 Jan;3(1):e13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling predicts survival in conventional renal cell carcinoma.
  • BACKGROUND: Conventional renal cell carcinoma (cRCC) accounts for most of the deaths due to kidney cancer.
  • Unsupervised hierarchical clustering analysis segregated cRCC into five gene expression subgroups.
  • A semisupervised learning algorithm (supervised principal components analysis) was applied to identify transcripts whose expression was associated with survival in the training set, and the performance of this gene expression-based survival predictor was assessed using the test set.
  • With this method, we identified 259 genes that accurately predicted disease-specific survival among patients in the independent validation group (p < 0.001).
  • In multivariate analysis, the gene expression predictor was a strong predictor of survival independent of tumor stage, grade, and performance status (p < 0.001).
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Kidney Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Cluster Analysis. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9 [11493696.001]
  • [Cites] Genome Res. 2001 Nov;11(11):1861-70 [11691851.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):94-6 [12519956.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6958-63 [12777628.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2225-32 [14634384.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3316-22 [15310775.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1272-8 [9562581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1691-6 [9853456.001]
  • [Cites] J Urol. 2005 Jan;173(1):48-51 [15592023.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • (PMID = 16318415.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1298943
  •  go-up   go-down


22. Ealey KN, Xuan W, Lu S, Archer MC: Colon carcinogenesis in liver-specific IGF-I-deficient (LID) mice. Int J Cancer; 2008 Jan 15;122(2):472-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinogenesis in liver-specific IGF-I-deficient (LID) mice.
  • The objective of this study was to determine the role of IGF-1 in colon carcinogenesis using liver-specific IGF-I deficient (LID) mice that exhibit 70% reductions in circulating IGF-I.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonic Neoplasms / genetics. Insulin / metabolism. Insulin-Like Growth Factor I / metabolism. Liver / metabolism
  • [MeSH-minor] Adenoma. Animals. Case-Control Studies. Disease Models, Animal. Female. Genotype. Male. Mice. Mice, Transgenic. Risk. Sex Factors

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17918153.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


23. Ramocki NM, Wilkins HR, Magness ST, Simmons JG, Scull BP, Lee GH, McNaughton KK, Lund PK: Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9. Endocrinology; 2008 Jan;149(1):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9.
  • Reduced apoptosis of crypt stem/progenitor cells and elevated insulin and IGFs are linked to colon cancer risk.
  • Using IRS-1(-/-), IRS-1(+/-), and IRS-1(+/+) mice, we tested the hypothesis that reduced IRS-1 expression increases apoptosis of intestinal crypt cells and protects against Apc(min/+) (Min)/beta-catenin-driven intestinal tumors.
  • Expression of Sox9, a transcriptional target of Tcf/beta-catenin and putative biomarker of crypt stem cells, was assessed in intestine of different IRS-1 genotypes and cell lines.
  • Irradiation-induced apoptosis was significantly increased in the crypts and crypt stem cell region of IRS-1-deficient mice.
  • Compared with IRS-1(+/+)/Min, IRS-1(-/-)/Min mice had fewer Sox9-positive cells in intestinal crypts and reduced Sox9 mRNA in intestine.
  • IRS-1 overexpression increased Sox9 expression in an intestinal epithelial cell line.
  • We conclude that even small reductions in endogenous IRS-1 increase apoptosis of crypt stem or progenitor cells, protect against beta-catenin-driven intestinal tumors, and reduce Sox9, a Tcf/beta-catenin target and putative stem/progenitor cell biomarker.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2004 Jul 5;166(1):37-47 [15240568.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40 [12050094.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):570-81 [15300589.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 28;183(1):280-5 [1311924.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):179-95 [1394796.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):186-90 [7526222.001]
  • [Cites] Stem Cells. 1996 Jul;14(4):452-9 [8843547.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):444-54 [9024298.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1976-8 [15731405.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):645-9 [15917419.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G381-7 [16093419.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29912-20 [15967802.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2076-81 [16172212.001]
  • [Cites] Oncology. 2005;69 Suppl 1:9-13 [16210870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14665-70 [16203988.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Dec;63(6):683-8 [16343104.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):17751-7 [16798748.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2038-46 [16675473.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1382-95 [17010943.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9302-14 [17030631.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S33-43 [17259557.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):539-46 [17681175.001]
  • [Cites] J Cell Biol. 2007 Aug 13;178(4):635-48 [17698607.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):397-403 [17700539.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5478-87 [10579310.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):745-53 [10680582.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):469-76 [10688867.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1070-6 [10706126.001]
  • [Cites] J Clin Invest. 2000 May;105(10):1437-45 [10811851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12103-8 [11035789.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3480-5 [11309311.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1865-70 [17267606.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Sep;283(3):E413-22 [12169433.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G457-64 [12121894.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10500-5 [17563382.001]
  • [Cites] J Endocrinol. 2002 Aug;174(2):309-19 [12176670.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G809-18 [12181198.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6035-8 [12414625.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1770-7 [12454832.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1015-9 [12807742.001]
  • [Cites] Development. 2003 Dec;130(23):5681-93 [14522876.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1710-1 [14657487.001]
  • [Cites] Radiat Res. 2004 Feb;161(2):123-36 [14731078.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):407-10 [14996863.001]
  • [Cites] Development. 2004 May;131(9):1891-901 [15056615.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1206-14 [15247132.001]
  • (PMID = 17916629.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM000678; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / CA-16086; United States / NIDDK NIH HHS / DK / R01 DK040247; United States / NCI NIH HHS / CA / T32 CA072319; United States / NIGMS NIH HHS / GM / K12 GM000678; United States / NIDDK NIH HHS / DK / DK-40247; United States / NCI NIH HHS / CA / CA-72319; United States / NIDDK NIH HHS / DK / P30-DK-34987
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / High Mobility Group Proteins; 0 / Insulin Receptor Substrate Proteins; 0 / Irs1 protein, mouse; 0 / SOX9 Transcription Factor; 0 / Sox9 protein, mouse; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2194604
  •  go-up   go-down


24. Watkins J, Balabaud C, Bioulac-Sage P, Sharma D, Dhillon A: Hepatocellular adenoma in advanced-stage fatty liver disease. Eur J Gastroenterol Hepatol; 2009 Aug;21(8):932-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular adenoma in advanced-stage fatty liver disease.
  • Hepatocellular adenomas are defined as benign hepatocellular neoplasms occurring in otherwise near normal liver and adenomatosis as 10 or more such lesions.
  • We present a case of a 45-year-old man with radiological adenomatosis, histologically confirmed with resection of one lesion, arising within advanced-stage nonalcoholic fatty liver disease (nearly cirrhotic).
  • Hepatocellular adenomas have recently been divided into four categories and the lesion in the present case had morphologic and immunohistochemical features of an inflammatory hepatocellular adenoma.
  • These findings demonstrate that, in contrast to the current dogma, nodules within advanced-stage liver disease may rarely be best classified as adenomas.
  • This should be considered in the radiological differential diagnosis when assessing a patient's suitability for transplantation.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Fatty Liver / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404203.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Agarwal R, Levinson AW, Schowinsky J, Su LM: Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma. Urology; 2007 Nov;70(5):1008.e17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma.
  • We report the case of a 39-year-old woman with a large right renal mass 20 cm in size with heterogeneous solid and cystic components as well as concurrent liver lesions suspicious for metastatic renal cell carcinoma.
  • Surgical extirpation of the renal mass and liver lesions was performed laparoscopically with the pathological analysis revealing a rare renal neoplasm--mixed epithelial and stromal tumor of the kidney--and adenomas of the liver.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


26. Gilbert KM, Venanzi CA: Hierarchical clustering analysis of flexible GBR 12909 dialkyl piperazine and piperidine analogs. J Comput Aided Mol Des; 2006 Apr;20(4):209-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hierarchical clustering analysis of flexible GBR 12909 dialkyl piperazine and piperidine analogs.
  • A comprehensive hierarchical clustering study of two GBR 12909 analogs was performed to identify representative conformers for input to three-dimensional quantitative structure-activity relationship studies of closely-related analogs.
  • Two data sets of more than 700 conformers each produced by random search conformational analysis of a piperazine and a piperidine GBR 12909 analog were studied.
  • Several clustering studies were carried out based on different feature sets that include the important pharmacophore elements.
  • The distance maps, the plot of the effective number of clusters versus actual number of clusters, and the novel derived clustering statistic, percentage change in the effective number of clusters, were shown to be useful in determining the appropriate clustering level.
  • This study illustrates the utility of using hierarchical clustering for the classification of conformers of highly flexible molecules in terms of the three-dimensional spatial orientation of key pharmacophore elements.
  • [MeSH-minor] Cluster Analysis. Dopamine Uptake Inhibitors / chemistry. Dopamine Uptake Inhibitors / pharmacology. Fuzzy Logic. Models, Molecular. Molecular Conformation. Molecular Structure. Piperidines / chemistry. Piperidines / pharmacology. Quantitative Structure-Activity Relationship. Thermodynamics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Chem Soc. 2003 Mar 5;125(9):2462-74 [12603134.001]
  • [Cites] J Med Chem. 2004 Jun 17;47(13):3388-98 [15189035.001]
  • [Cites] J Med Chem. 2000 Mar 23;43(6):1085-93 [10737741.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4861-72 [9822555.001]
  • [Cites] J Am Chem Soc. 2003 Mar 12;125(10):3101-7 [12617677.001]
  • [Cites] J Med Chem. 1997 Feb 28;40(5):705-16 [9057857.001]
  • [Cites] J Med Chem. 1996 Feb 2;39(3):749-56 [8576918.001]
  • [Cites] J Med Chem. 1991 Sep;34(9):2719-25 [1895292.001]
  • [Cites] J Med Chem. 2000 Nov 2;43(22):4151-9 [11063611.001]
  • [Cites] J Comput Aided Mol Des. 1998 Jul;12(4):383-96 [9777496.001]
  • [Cites] J Med Chem. 2001 May 10;44(10):1509-15 [11334561.001]
  • [Cites] J Med Chem. 1994 Sep 2;37(18):2865-73 [8071935.001]
  • [Cites] J Med Chem. 1999 Jan 28;42(2):249-59 [9925730.001]
  • [Cites] J Med Chem. 2003 Apr 10;46(8):1293-305 [12672230.001]
  • [Cites] J Med Chem. 2002 Apr 11;45(8):1577-84 [11931612.001]
  • [Cites] Proteins. 1991;11(4):297-313 [1758884.001]
  • [Cites] J Med Chem. 2005 Dec 1;48(24):7773-80 [16302816.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4876-82 [9988729.001]
  • [Cites] Neuropharmacology. 2005 Nov;49(6):780-90 [16216288.001]
  • [Cites] J Comput Aided Mol Des. 2004 Nov;18(11):719-38 [15865064.001]
  • [Cites] J Med Chem. 1998 Mar 12;41(6):864-76 [9526561.001]
  • [Cites] J Am Chem Soc. 1988 Aug 1;110(18):5959-67 [22148765.001]
  • [Cites] J Mol Biol. 2003 Jan 17;325(3):515-30 [12498800.001]
  • [Cites] J Med Chem. 2003 May 22;46(11):2205-15 [12747792.001]
  • [Cites] J Med Chem. 2002 Sep 12;45(19):4119-27 [12213055.001]
  • [Cites] Pharm Res. 1995 Oct;12(10):1430-4 [8584475.001]
  • [Cites] J Med Chem. 2004 May 6;47(10):2499-510 [15115393.001]
  • [Cites] J Chem Inf Model. 2005 May-Jun;45(3):610-23 [15921451.001]
  • [Cites] Chem Rev. 2000 Mar 8;100(3):925-1024 [11749256.001]
  • [Cites] J Comput Chem. 2006 Apr 15;27(5):609-20 [16470669.001]
  • [Cites] J Comput Aided Mol Des. 1998 Nov;12(6):563-72 [9879504.001]
  • [Cites] J Comput Aided Mol Des. 2000 Mar;14(3):251-64 [10756480.001]
  • [Cites] J Comput Aided Mol Des. 2000 Feb;14(2):135-46 [10721502.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Oct;40(2):387-97 [1839568.001]
  • [Cites] J Med Chem. 2004 Oct 7;47(21):5101-13 [15456254.001]
  • [Cites] J Med Chem. 2004 Dec 2;47(25):6137-43 [15566285.001]
  • [Cites] Synapse. 2001 Feb;39(2):175-81 [11180505.001]
  • [Cites] Trends Neurosci. 1991 Jul;14(7):299-302 [1719677.001]
  • [Cites] Bioorg Med Chem. 2006 Feb 1;14(3):666-75 [16216517.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3649-59 [12166938.001]
  • [Cites] J Med Chem. 2002 Sep 12;45(19):4371-4 [12213078.001]
  • [Cites] J Chem Inf Comput Sci. 1998 May-Jun;38(3):506-10 [9611786.001]
  • [Cites] Bioorg Med Chem. 2001 Jul;9(7):1753-64 [11425577.001]
  • [Cites] J Med Chem. 1999 Sep 9;42(18):3502-9 [10479283.001]
  • [Cites] J Med Chem. 2004 Jan 1;47(1):133-42 [14695827.001]
  • [Cites] Bioorg Med Chem. 1995 Apr;3(4):411-28 [8581425.001]
  • [Cites] Pharmacol Biochem Behav. 1996 Apr;53(4):911-8 [8801597.001]
  • (PMID = 16855855.001).
  • [ISSN] 0920-654X
  • [Journal-full-title] Journal of computer-aided molecular design
  • [ISO-abbreviation] J. Comput. Aided Mol. Des.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA015555; United States / NIDA NIH HHS / DA / DA018153
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dopamine Uptake Inhibitors; 0 / Piperazines; 0 / Piperidines; 90X28IKH43 / vanoxerine
  •  go-up   go-down


27. Vaahtio M, Peltola T, Hentunen T, Ylänen H, Areva S, Wolke J, Salonen JI: The properties of biomimetically processed calcium phosphate on bioactive ceramics and their response on bone cells. J Mater Sci Mater Med; 2006 Nov;17(11):1113-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The properties of biomimetically processed calcium phosphate on bioactive ceramics and their response on bone cells.
  • This study looks for grounds to alter the chemical composition (phosphate, calcium, silica and carbonate), dissolution properties, structure and nanotopography of the biomimetically processed surfaces on bioactive ceramics to optimize their shown ability to influence bone cell behaviour and production of new bone.
  • The CaP so formed in R-SBF with faster precipitation is more amorphous than the bonelike HCA formed in C-SBF.
  • [MeSH-minor] Animals. Animals, Newborn. Cell Line, Tumor. Cells, Cultured. Humans. Rats

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Mater Res A. 2004 May 1;69(2):314-22 [15058004.001]
  • [Cites] Biomaterials. 2003 Jul;24(16):2711-9 [12711517.001]
  • [Cites] J Biomed Mater Res. 2001 Mar 15;54(4):560-6 [11426602.001]
  • [Cites] J Biomed Mater Res. 2000 Sep 5;51(3):475-83 [10880091.001]
  • [Cites] Clin Chem. 2000 Nov;46(11):1751-4 [11067809.001]
  • [Cites] Biomaterials. 2003 Sep;24(20):3383-93 [12809766.001]
  • [Cites] Biomaterials. 2004 Aug;25(18):3963-72 [15046886.001]
  • [Cites] J Biomed Mater Res. 1990 Jun;24(6):721-34 [2361964.001]
  • [Cites] Biomaterials. 1997 Feb;18(4):295-303 [9068890.001]
  • [Cites] J Bone Miner Res. 1989 Dec;4(6):817-25 [2692403.001]
  • [Cites] Biomaterials. 2002 Jul;23(14):2945-54 [12069336.001]
  • [Cites] J Biomed Mater Res. 1996 Apr;30(4):509-14 [8847359.001]
  • [Cites] J Biomed Mater Res A. 2004 Aug 1;70(2):169-78 [15227661.001]
  • [Cites] J Biomed Mater Res. 1999 May;45(2):140-7 [10397968.001]
  • [Cites] Biomaterials. 1999 Dec;20(23-24):2287-303 [10614935.001]
  • [Cites] Biomaterials. 2004 Jun;25(13):2547-55 [14751740.001]
  • [Cites] J Bone Miner Res. 1998 Oct;13(10):1530-8 [9783541.001]
  • [Cites] Ann Chir Gynaecol. 1999;88(3):237-45 [10532567.001]
  • [Cites] J Biomed Mater Res A. 2003 Feb 1;64(2):339-48 [12522821.001]
  • [Cites] Bone. 1998 Mar;22(3):201-9 [9514212.001]
  • [Cites] J Mater Sci Mater Med. 2001 Aug;12(8):659-64 [15348234.001]
  • [Cites] Endocrinology. 1987 Feb;120(2):602-8 [3467966.001]
  • [Cites] J Biomed Mater Res. 1997 Jul;36(1):109-17 [9212395.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 24;276(2):461-5 [11027497.001]
  • [Cites] Anal Chem. 1999 Jan 1;71(1):149-53 [21662937.001]
  • [Cites] J Mater Sci Mater Med. 1997 Jan;8(1):1-4 [15348834.001]
  • [Cites] J Biomed Mater Res. 2001 May;55(2):151-7 [11255166.001]
  • [Cites] J Biomed Mater Res A. 2003 Dec 15;67(4):1205-18 [14624507.001]
  • [Cites] J Biomed Mater Res. 1999 Jan;44(1):12-21 [10397900.001]
  • [Cites] Biomaterials. 1991 Mar;12(2):155-63 [1878450.001]
  • [Cites] Biomaterials. 2001 Jan;22(2):135-50 [11101158.001]
  • [Cites] J Biomed Mater Res. 1999 Dec 5;47(3):424-33 [10487896.001]
  • [Cites] J Biomed Mater Res. 2001 Aug;56(2):208-15 [11340590.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):1-9 [11978003.001]
  • [Cites] J Mater Sci Mater Med. 2003 Sep;14(9):731-8 [15348391.001]
  • [Cites] Biomaterials. 1999 Sep;20(18):1727-41 [10503974.001]
  • (PMID = 17122926.001).
  • [ISSN] 0957-4530
  • [Journal-full-title] Journal of materials science. Materials in medicine
  • [ISO-abbreviation] J Mater Sci Mater Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 85422-94-2 / Glass ceramics; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


28. Kadam RU, Roy N: Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors. Bioorg Med Chem Lett; 2006 Oct 1;16(19):5136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors.
  • We report herein, the development of cluster analysis-based 2D-QSAR models for LpxC inhibition.
  • Principal component analysis (PCA), hierarchical cluster analysis (HCA), and genetic function approximation (GFA) were employed for the development of the QSAR model.
  • Descriptor-based cluster analysis indicated that the three-structural classes of LpxC inhibitors studied belonged to two clusters.
  • [MeSH-minor] Cluster Analysis. Drug Evaluation, Preclinical / methods. Inhibitory Concentration 50

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879960.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 3.5.- / Amidohydrolases; EC 3.5.1.- / LpxC deacetylase, Pseudomonas
  •  go-up   go-down


29. Zhang YB, Lin HF, Lv L, Hua WG, Tian F, Shen GZ, Xia ZL, Jin XP: [In vitro evaluation of cutaneous allergic reaction induced by chemicals using dendritic cells]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Mar;26(3):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In vitro evaluation of cutaneous allergic reaction induced by chemicals using dendritic cells].
  • OBJECTIVE: To investigate the use of dendritic cells derived from mice bone marrow to evaluate the cutaneous allergic reaction induced by chemical sensitizers.
  • METHODS: Dendritic cells derived from mice bone marrow were cultured and administrated with 2, 4-dinitrochlorobenzene (DNCB), nickel sulfate (NiSO4), sodium dodecyl sulfate (SDS) and hexyl cinnamic aldehyde (HCA), respectively.
  • Cell membrane molecule CD86 and extracellular IL-1 beta, IL-6 and IL-12 were detected after 0, 1, 6, 12, 24, 36, 48 hour's administration, respectively.
  • RESULTS: CD86 expression reached the highest level after exposure to DNCB for 48 h, and increased by about 279% compared with the control (P < 0.05), while it was lower than that of control after administrated with NiSO4 and HCA for 1 h and 6 h, and SDS for 36 h, respectively (P < 0.05).
  • Extracellular IL-1 beta increased greatly after exposure to NiSO4 just for 1 h, with the maximum at 48 h (298 pg/ml, P < 0.05), and after exposure to HCA for 6 h, with maximum at 48 h (84 pg/ml, P < 0.05).
  • After exposure to HCA, extracellular IL-6 reached the maximum at 1 h (1403 pg/ml), and then it was decreased quickly, but still higher than the control (P < 0.05), while it didn't change significantly after treatment with DNCB and SDS, compared with the control (P > 0.05).
  • CONCLUSION: Chemical sensitizer DNCB could induce the high expression of CD86 on DC membrane, and NiSO4 and HCA could induce DC to release IL-1 beta and IL-6.
  • [MeSH-major] Dendritic Cells / drug effects. Dinitrochlorobenzene / pharmacology. Nickel / pharmacology. Sodium Dodecyl Sulfate / pharmacology
  • [MeSH-minor] Animals. Antigens, CD86 / metabolism. Cells, Cultured. Interleukin-12 / metabolism. Interleukin-1beta / metabolism. Interleukin-6 / metabolism. Mice. Mice, Inbred C57BL

  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. NICKEL SULFATE .
  • Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761792.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD86; 0 / Interleukin-1beta; 0 / Interleukin-6; 187348-17-0 / Interleukin-12; 368GB5141J / Sodium Dodecyl Sulfate; 4FLT4T3WUN / nickel sulfate; 7OV03QG267 / Nickel; GE3IBT7BMN / Dinitrochlorobenzene
  •  go-up   go-down


30. Culp SJ, Mellick PW, Trotter RW, Greenlees KJ, Kodell RL, Beland FA: Carcinogenicity of malachite green chloride and leucomalachite green in B6C3F1 mice and F344 rats. Food Chem Toxicol; 2006 Aug;44(8):1204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female rats exposed to malachite green chloride had increased incidences of thyroid gland follicular cell adenoma or carcinoma and hepatocellular adenoma, and a dose-related increasing trend in mammary gland carcinoma.
  • Female rats fed malachite green chloride and female and male rats fed leucomalachite green had a dose-related decreasing trend in the incidence of mononuclear cell leukemia.
  • In male rats fed leucomalachite green there was a decreasing trend in pituitary gland adenoma and an increasing trend in interstitial cell adenoma of the testis.
  • Female mice fed leucomalachite green had a dose-related increasing trend in the incidence of hepatocellular adenoma or carcinoma, with the incidence being significant in the highest dose group.
  • [MeSH-minor] Animals. Body Weight / drug effects. Carcinogenicity Tests. Eating / drug effects. Female. Male. Mice. Mice, Inbred C57BL. Rats. Rats, Inbred F344. Statistics, Nonparametric. Survival Analysis

  • Hazardous Substances Data Bank. Leucomalachite green .
  • Hazardous Substances Data Bank. MALACHITE GREEN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554117.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Fungicides, Industrial; 0 / Rosaniline Dyes; 12058M7ORO / malachite green; 8U61G37Z20 / leucomalachite green
  •  go-up   go-down


31. Bahirwani R, Reddy KR: Review article: the evaluation of solitary liver masses. Aliment Pharmacol Ther; 2008 Oct 15;28(8):953-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: the evaluation of solitary liver masses.
  • BACKGROUND: The increasing use of imaging modalities has led to the detection of more liver masses.
  • The differential diagnosis of a focal liver mass includes a host of benign as well as malignant conditions.
  • AIM: To provide a comprehensive review on the commonly encountered liver masses, and to help guide an approach to their evaluation and management.
  • RESULTS: While most incidentally noted liver masses are benign, it may be difficult to differentiate them from those that are malignant.
  • Furthermore, some benign lesions have malignant potential.
  • The less frequently encountered hepatic adenomas are diagnosed radiologically in those with the appropriate clinical background and the absence of radiological features to suggest haemangioma or focal nodular hyperplasia.
  • CONCLUSIONS: A reasonable approach to the diagnosis, follow-up and management of liver masses is based on a rudimentary knowledge of their presentation, associated clinical and laboratory features, natural history and available treatment options.
  • Most often, the so called 'incidentalomas' are benign and require patient reassurance.
  • [MeSH-major] Adenoma, Liver Cell / diagnosis. Cystadenoma / diagnosis. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Caroli Disease / diagnosis. Cysts / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18643922.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 85
  •  go-up   go-down


32. Haldenwang PL, Strauch JT, Amann I, Klein T, Sterner-Kock A, Christ H, Wahlers T: Impact of pump flow rate during selective cerebral perfusion on cerebral hemodynamics and metabolism. Ann Thorac Surg; 2010 Dec;90(6):1975-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although hypothermic selective cerebral perfusion (SCP) is widely used for cerebral protection during aortic surgery, little is known about the ideal pump-flow management during this procedure.
  • After 10 minutes of hypothermic circulatory arrest, the animals were randomly assigned to 60 minutes of SCP at two different pump flow rates: 8 mL·kg(-1)·min(-1) (n = 7) and 18 mL·kg(-1)·min(-1) (n = 7).
  • [MeSH-minor] Animals. Aorta, Thoracic / surgery. Disease Models, Animal. Female. Intracranial Pressure / physiology. Oxygen Consumption. Regional Blood Flow / physiology. Stroke / prevention & control. Swine. Vascular Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Thorac Surg. 2010 Dec;90(6):1984 [21095349.001]
  • (PMID = 21095348.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Kiralj R, Ferreira MM: Chemometric analysis of the multidrug resistance in strains of Penicillium digitatum. SAR QSAR Environ Res; 2008 Jan-Mar;19(1-2):55-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemometric analysis of the multidrug resistance in strains of Penicillium digitatum.
  • Multidrug resistance activities pECr50 of diverse strains of pathogenic fungus Penicillium digitatum against seven toxicants were studied by Principal Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA).
  • This data set was studied by PCA and HCA, and was correlated with the genome descriptor PCR for expression of gene CYP51 by Partial Least Squares (PLS) regression.
  • Both analyses of pECr50 data and of fungal growth data have identified baseline resistance character, origin and target fruits of the fungal strains.
  • In addition, the analysis of fungal growth data shows that fungal growth morphology is multivariate by nature, meaning that experimental data can be explored more intensely than in usual practice.
  • [MeSH-minor] Cluster Analysis. Cytochrome P-450 Enzyme System / genetics. Fungal Proteins / genetics. Principal Component Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311634.001).
  • [ISSN] 1062-936X
  • [Journal-full-title] SAR and QSAR in environmental research
  • [ISO-abbreviation] SAR QSAR Environ Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Fungal Proteins; 0 / Fungicides, Industrial; 9035-51-2 / Cytochrome P-450 Enzyme System
  •  go-up   go-down


34. Satoh J: [Molecular biomarkers for prediction of multiple sclerosis relapse]. Nihon Rinsho; 2008 Jun;66(6):1103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system white matter mediated by an autoimmune process, whose development is triggered by a complex interplay of multiple genetic, infectious and environmental factors.
  • DNA microarray is a novel technology that allows us to systematically monitor the expression of whole human genome in disease-affected tissues and cells.
  • By using DNA microarray, we have recently studied gene expression profile of peripheral blood T cells isolated from clinically active MS patients and healthy controls, and from MS patients in relapse and during remission.
  • Hierarchical clustering analysis of the discriminator genes established classification of MS subgroups that exhibit distinct gene expression profiles and relapse-specific molecular signatures.
  • [MeSH-major] Biomarkers / analysis. Multiple Sclerosis / diagnosis. Multiple Sclerosis / genetics
  • [MeSH-minor] Humans. Protein Array Analysis. Recurrence

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540355.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 40
  •  go-up   go-down


36. Yamamoto T, Kikkawa R, Yamada H, Horii I: Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. J Toxicol Sci; 2006 Feb;31(1):49-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants.
  • Acetaminophen (APAP), amiodarone (AMD), tetracycline (TC) and carbon tetrachloride (CTC) were administered to male rats by gavages and the liver at 24 hr post-dosing was applied to the proteomic experiment.
  • Protein expression in the liver was investigated by 2-dimensional gel electrophoresis (2DE), and spots showing a significantly different expression in treated versus control group were excised from gels and identified by Q-Tof mass spectrometer.
  • Moreover, hierarchical clustering analysis using 2D-gel spots information revealed the possibility to differentiate the groups based on their toxicity levels such as severity of liver damage.
  • [MeSH-major] Acetaminophen / toxicity. Amiodarone / toxicity. Carbon Tetrachloride / toxicity. Liver / drug effects. Proteins / metabolism. Tetracycline / toxicity


37. Ferrara DE, Weiss D, Carnell PH, Vito RP, Vega D, Gao X, Nie S, Taylor WR: Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy. Am J Physiol Regul Integr Comp Physiol; 2006 Jan;290(1):R114-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy.
  • We studied human coronary arteries (HCAs) and mouse aortas with a modified immunohistochemical (IHC) "en face" method using quantum dot (Qdot) bioconjugates and two-photon excitation laser scanning microscopy (TPELSM).
  • Detailed cell structures, such as the granular appearance of von Willebrand factor (VWF) and the subcellular distribution of endothelial nitric oxide synthase, were visualized using green dots (525 nm), even when the emission maximum of these Qdots overlapped that of tissue autofluorescence (510-520 nm).
  • In addition, sensitive fluorescence quantification of vascular cell adhesion molecule 1 expression at areas of varying hemodynamics (intercostal branches vs. nonbranching areas) was performed in normal C57Bl/6 mice.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16223849.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P20 GM072069; United States / NCI NIH HHS / CA / R01 CA108468; United States / PHS HHS / / R-01-L70531; United States / NIH HHS / NH / U0-1-NH-080711
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


38. Gutiérrez NC, López-Pérez R, Hernández JM, Isidro I, González B, Delgado M, Fermiñán E, García JL, Vázquez L, González M, San Miguel JF: Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia; 2005 Mar;19(3):402-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow samples from 43 adult patients with de novo diagnosed acute myeloid leukemia (AML)--10 acute promyelocytic leukemias (APL) with t(15;17), four AML with inv(16), seven monocytic leukemias and 22 nonmonocytic leukemias--were analyzed using high-density oligonucleotide microarrays.
  • Hierarchical clustering analysis segregated APL, AML with inv(16), monocytic leukemias and the remaining AML into separate groups.
  • Quantitative RT-PCR performed for 18 out of these predictor genes confirmed microarray results.
  • Genes involved in cell adhesion represented the most altered functional category in monocytic leukemias.
  • In the latter cluster, CD34 upregulation and serine proteases downregulation is consistent with a maturation arrest and lack of granulocytic differentiation.
  • [MeSH-minor] Adolescent. Adult. Aged. Cluster Analysis. Female. Humans. Leukemia, Monocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Male. Middle Aged. Phylogeny. Retrospective Studies


39. Sherman M: Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis; 2010 Jul;42 Suppl 3:S215-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: New and emerging risks.
  • The underlying liver diseases that put patients at risk for the development of hepatocellular carcinoma (HCC) are well known.
  • Therefore within the disease groups (hepatitis B, cirrhosis, etc.,) there are other factors that indicate greater or lesser risk.
  • In addition to the common causes of liver disease that are recognized to be causes of HCC non-alcoholic fatty liver disease and possibly diabetes are newly emerging risk factors.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Hepatocellular / virology. Hepatitis B, Chronic / complications. Liver Cirrhosis / complications. Liver Neoplasms / virology
  • [MeSH-minor] Age Factors. Disease Progression. Fatty Liver / complications. Female. Hepatitis C, Chronic / complications. Hepatocyte Nuclear Factor 1 / genetics. Humans. Male. Middle Aged. Mutation. Risk Factors. Sex Factors. beta Catenin / genetics

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.. All rights reserved.
  • (PMID = 20547306.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / beta Catenin; 126548-29-6 / Hepatocyte Nuclear Factor 1
  •  go-up   go-down


40. Pavón JL, Peña AG, Pinto CG, Cordero BM: Differentiation of types of crude oils in polluted soil samples by headspace-fast gas chromatography-mass spectrometry. J Chromatogr A; 2006 Dec 22;1137(1):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemometric treatments, such as hierarchical cluster analysis (HCA), principal component analysis (PCA), and soft independent modelling of class analogy (SIMCA) were applied to the signals obtained for the different samples.
  • [MeSH-major] Gas Chromatography-Mass Spectrometry / methods. Petroleum / analysis. Soil Pollutants / analysis
  • [MeSH-minor] Pilot Projects. Principal Component Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056051.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Petroleum; 0 / Soil Pollutants
  •  go-up   go-down


41. Gasparri F, Cappella P, Galvani A: Multiparametric cell cycle analysis by automated microscopy. J Biomol Screen; 2006 Sep;11(6):586-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiparametric cell cycle analysis by automated microscopy.
  • Cell cycle analysis using flow cytometry (FC) to measure cellular DNA content is a common procedure in drug mechanism of action studies.
  • Although this technique lends itself readily to cell lines that grow in suspension, adherent cell cultures must be resuspended in a cumbersome and potentially invasive procedure that normally involves trypsinization and mechanical agitation of monolayer cultures.
  • High-content analysis (HCA), an automated microscopy-based technology, is well suited to analysis of monolayer cell cultures but provides intrinsically less accurate determination of cellular DNA content than does FC and thus is not the method of choice for cell cycle analysis.
  • Using Cellomics's ArrayScan reader, the authors have developed a 4-color multiparametric HCA approach for cell cycle analysis of adherent cells based on detection of DNA content (4,6-diamidino-2-phenylindole [DAPI] fluorescence), together with the known cell cycle markers bromo-2-deoxyuridine (BrdU) incorporation, cyclin B1 expression, and histone H3 (Ser28) phosphorylation within a single cell population.
  • Considering all 4 markers together, a reliable and accurate quantification of cell cycle phases was possible, as compared with flow cytometric analysis.
  • Using this assay, specific cell cycle blocks induced by treatment with thymidine, paclitaxel, or nocodazole as test drugs were easily monitored in adherent cultures of U-2 OS osteosarcoma cells.
  • [MeSH-major] Cell Cycle / physiology. Flow Cytometry / instrumentation. Microscopy / instrumentation
  • [MeSH-minor] Automation. Bromodeoxyuridine / pharmacology. Cell Division / drug effects. Cells, Cultured. DNA / analysis. Humans

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844964.001).
  • [ISSN] 1087-0571
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


42. Pousios D, Velissaris T, Duggan S, Tsang G: Floating intra-aortic thrombus presenting as distal arterial embolism. Interact Cardiovasc Thorac Surg; 2009 Sep;9(3):532-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Floating thrombi in the aorta are a rare finding in the absence of any coagulation abnormality.
  • There was no pre-existing clotting abnormality.
  • Under temporary hypothermic circulatory arrest, the ascending aorta was opened.
  • Only a few cases of intra-aortic thrombus without any coagulation abnormality basis are described in literature.
  • [MeSH-minor] Acute Disease. Administration, Oral. Anticoagulants / administration & dosage. Aortography / methods. Blood Vessel Prosthesis Implantation. Cardiopulmonary Bypass. Circulatory Arrest, Deep Hypothermia Induced. Female. Humans. Ischemic Attack, Transient / etiology. Magnetic Resonance Angiography. Middle Aged. Sternum / surgery. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454418.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


43. Singhal A, Shrago SS, Li SF, Huang Y, Kohli V: A hepatic metastasis from pleomorphic adenoma of salivary gland: an unusual presentation. Hepatogastroenterology; 2010 Mar-Apr;57(98):330-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hepatic metastasis from pleomorphic adenoma of salivary gland: an unusual presentation.
  • Metastasizing pleomorphic adenoma (PA) is a rare condition displaying benign histological features as of PA in the metastatic lesion.
  • The present study report a case of 46 years old male presented with space occupying lesion in the right lobe of liver.
  • Patient underwent extended right hepatectomy for space occupying lesion in liver and the histological features were suggestive of metastatic benign pleomorphic adenoma.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Liver Neoplasms / secondary. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Imaging. Humans. Male. Middle Aged


44. Elder I, Fisher Z, Laipis PJ, Tu C, McKenna R, Silverman DN: Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III. Proteins; 2007 Jul 1;68(1):337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III.
  • We report the X-ray crystal structures and rate constants for proton transfer in site-specific mutants of human carbonic anhydrase III (HCA III) that place a histidine residue in the active-site cavity: K64H, R67H, and K64H-R67N HCA III.
  • Prior evidence from the exchange of 18O between CO2 and water measured by mass spectrometry shows each mutant to have enhanced proton transfer in catalysis compared with wild-type HCA III.
  • However, His64 in K64H and K64H-R67N HCA III have at most a capacity for proton transfer that is only 13% that of His64 in HCA II.
  • This reduced rate in mutants of HCA III is associated with a constrained side-chain conformation of His64, which is oriented outward, away from the active-site zinc in the crystal structures.
  • This conformation appears stabilized by a prominent pi stacking interaction of the imidazole ring of His64 with the indole ring of Trp5 in mutants of HCA III.
  • This single orientation of His64 in K64H HCA III predominates also in a double mutant K64H-R67N HCA III, indicating that the positive charge of Arg67 does not influence the observed conformation of His64 in the crystal structure.
  • Hence, the structures and catalytic activity of these mutants of HCA III containing His64 account only in small part for the lower activity of this isozyme compared with HCA II.
  • His67 in R67H HCA III was also shown to be a proton shuttle residue, having a capacity for proton transfer that was approximately four times that of His64 in K64H HCA III.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc.
  • (PMID = 17427958.001).
  • [ISSN] 1097-0134
  • [Journal-full-title] Proteins
  • [ISO-abbreviation] Proteins
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 25154
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; EC 4.2.1.- / Carbonic Anhydrase III
  •  go-up   go-down


45. Allmark E: Hepatic adenoma: an unusual cause of abdominal pain. Emerg Nurse; 2007 Jun;15(3):18-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic adenoma: an unusual cause of abdominal pain.
  • [MeSH-major] Abdominal Pain / etiology. Adenoma / diagnosis. Adenoma / therapy. Emergency Treatment / methods. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Emergencies / nursing. Emergency Nursing. Female. Humans. Nursing Assessment. Rare Diseases. Risk Factors. Rupture, Spontaneous. Shock / etiology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for hepatic adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760235.001).
  • [ISSN] 1354-5752
  • [Journal-full-title] Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association
  • [ISO-abbreviation] Emerg Nurse
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


46. Szalóki T, Tóth V, Tiszlavicz L, Czakó L: [Diagnostic and therapeutic use of endoscopic resection of gastric mucosa]. Orv Hetil; 2006 Mar 19;147(11):501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: EMR is a widely used treatment option for gastric adenoma and early gastric cancer, but, there are no data on its use in Hungary.
  • PATIENTS: 44 patients (30 females, 14 males, mean age: 67 years) were studied between 1994 and 2005; 33 had severe concomitant diseases (liver cirrhosis or severe cardiovascular disease).
  • The diagnosis at first biopsy was in situ carcinoma in 3, adenoma with no dysplasia in 19, adenoma with low-grade dysplasia in 2, adenoma with moderate-grade dysplasia in 6, adenoma with high-grade dysplasia in 7, and hyperplastic lesion in 17 cases.
  • The histology of EMR revealed in situ carcinoma in 5, carcinoid in 1, gastrointestinal stromal tumor in 1, adenoma with no dysplasia in 14, adenoma with low-grade dysplasia in 3, adenoma with moderate-grade dysplasia in 9, adenoma with high-grade dysplasia in 1, hyperplastic lesion in 21, and no diagnosis in 1 case.
  • A Nd YAG laser was used in this patient with in situ carcinoma, where the resection margin was not free of cancer cells.
  • Among adenoma cases one recurrence was seen in the same place and one in another location.
  • One hyperplastic residuum occurred and in one case adenoma has grown in the same place.
  • Biopsy is generally unreliable to diagnose gastric adenoma.
  • Lesions should be fully resected by EMR for a final diagnosis and (depending on the lesion size and type) possibly definitive treatment.
  • [MeSH-major] Gastric Mucosa / surgery. Gastroscopy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / surgery. Laser Therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607858.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


47. Ocama P, Katwere M, Piloya T, Feld J, Opio KC, Kambugu A, Katabira E, Thomas D, Colebunders R, Ronald A: The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci; 2008 Mar;8(1):8-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
  • BACKGROUND: Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections.
  • OBJECTIVE: To describe the spectrum of liver diseases in HIV-infected patients attending an HIV clinic in Kampala, Uganda.
  • METHOD: Consecutive patients presenting with jaundice, right upper quadrant pain with fever or malaise, ascites and/or tender hepatomegaly were recruited and underwent investigations to evaluate the cause of their liver disease.
  • Although 14 (61%) patients with drug-induced liver disease presented with jaundice, all recovered with drug discontinuation.
  • Other diagnoses included alcoholic liver disease, AIDS cholangiopathy, hepatocellular carcinoma, schistosomiasis, haemangioma and hepatic adenoma.
  • Twelve (16%) patients died during follow-up of which 7 (9%) died because of liver disease.
  • CONCLUSION: Drug history, liver enzyme studies, ultrasound, and hepatitis B and C investigations identified the probable etiology in 60 (78%) of 77 patients with HIV infection presenting with symptoms and/or signs of liver disease.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antitubercular Agents / adverse effects. HIV Infections / complications. HIV Infections / drug therapy. Isoniazid / adverse effects. Liver Diseases / epidemiology. Nevirapine / adverse effects. Reverse Transcriptase Inhibitors / adverse effects
  • [MeSH-minor] Comorbidity. Drug-Induced Liver Injury. Female. Follow-Up Studies. Humans. Immunocompromised Host. Incidence. Liver Neoplasms / epidemiology. Male. Prevalence. Time Factors. Treatment Outcome. Tuberculosis / drug therapy. Tuberculosis / epidemiology. Uganda

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. NEVIRAPINE .
  • Hazardous Substances Data Bank. ISONIAZID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Jan 5;283(1):74-80 [10632283.001]
  • [Cites] J Int Assoc Physicians AIDS Care (Chic). 2007 Jun;6(2):83-6 [17537997.001]
  • [Cites] Med Sci Monit. 2001 Jul-Aug;7(4):729-36 [11433202.001]
  • [Cites] East Afr Med J. 2002 Feb;79(2):68-72 [12380879.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S80-9 [14986279.001]
  • [Cites] Clin Infect Dis. 2004 Aug 15;39(4):488-96 [15356811.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):209-12 [15602740.001]
  • [Cites] East Afr Med J. 2005 Apr;82(4):170-2 [16122083.001]
  • [Cites] Ann Hepatol. 2005 Jul-Sep;4(3):188-91 [16177658.001]
  • [Cites] J Antimicrob Chemother. 2005 Dec;56(6):1087-93 [16269552.001]
  • [Cites] Antivir Ther. 2005;10(8):953-65 [16430201.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5005-9 [17075119.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6879-83 [17106941.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1553-8 [17134360.001]
  • [Cites] AIDS Rev. 2007 Jan-Mar;9(1):40-53 [17474312.001]
  • [Cites] East Afr Med J. 2000 Jan;77(1):13-5 [10944831.001]
  • (PMID = 19357726.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antitubercular Agents; 0 / Reverse Transcriptase Inhibitors; 99DK7FVK1H / Nevirapine; V83O1VOZ8L / Isoniazid
  • [Other-IDs] NLM/ PMC2408539
  •  go-up   go-down


48. Mantone J: HCA hits gain-sharing hurdle. Vendor objects to comments on usage levels. Mod Healthc; 2006 Feb 13;36(7):12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA hits gain-sharing hurdle. Vendor objects to comments on usage levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515059.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


49. Gitto R, Agnello S, Ferro S, Vullo D, Supuran CT, Chimirri A: Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors. ChemMedChem; 2010 Jun 7;5(6):823-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349499.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Protein Isoforms; 0 / Sulfonamides; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase VI
  •  go-up   go-down


50. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C: Hepatocellular adenoma: what is new in 2008. Hepatol Int; 2008 Sep;2(3):316-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular adenoma: what is new in 2008.
  • Patients (85%) with hepatocellular adenoma (HCA) are women taking oral contraceptives.
  • They can be divided into four subgroups according to their genotype/phenotype features. (1) Hepatocyte nuclear factor 1alpha (HNF1alpha) biallelic somatic mutations are observed in 35% of the HCA cases.
  • HNF1alpha-mutated HCA are most of the time, highly steatotic, with a lack of expression of liver fatty acid binding protein (LFABP) in immunohistochemistry analyses.
  • An HNF1alpha germline mutation is observed in less than 5% of HCA cases and can be associated with MODY 3 diabetes. (2) An activating beta-catenin mutation was found in 10% of HCA.
  • These beta-catenin activated HCAs are observed in men and women, and specific risk factors, such as male hormone administration or glycogenosis, are associated with their development.
  • Immunohistochemistry studies show that these HCAs overexpress beta-catenin (nuclear and cytoplasmic) and glutamine synthetase.
  • This group of tumours has a higher risk of malignant transformation into hepatocellular carcinoma. (3) Inflammatory HCAs are observed in 40% of the cases, and they are most frequent in women but are also found in men.
  • An additional 10% of inflammatory HCAs express beta-catenin, and are also at risk of malignant transformation. (4) Currently, less than 10% of HCAs are unclassified.
  • It is hoped that in the near future it will be possible with clinical, biological and imaging data to predict in which of the 2 major groups (HNF1alpha-mutated HCA and inflammatory HCA) the patient belongs and to propose better guidelines in terms of surveillance and treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2008 Jan;48(1):163-70 [17997499.001]
  • [Cites] J Pediatr Surg. 2006 Jun;41(6):1149-52 [16769351.001]
  • [Cites] J Vasc Interv Radiol. 2007 Jul;18(7):862-7 [17609445.001]
  • [Cites] Hepatology. 2007 Jul;46(1):140-6 [17596890.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2611-6 [17363580.001]
  • [Cites] Gut. 2007 Feb;56(2):307-9 [17303609.001]
  • [Cites] J Hepatol. 2007 Mar;46(3):521-7 [17239484.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1495-502 [17051603.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):883-6 [17049664.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):767-9 [17034896.001]
  • [Cites] Hepatology. 2006 Mar;43(3):401-4 [16496344.001]
  • [Cites] Hepatology. 2006 Mar;43(3):515-24 [16496320.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1211-8 [15887105.001]
  • [Cites] J Clin Gastroenterol. 2005 May-Jun;39(5):401-12 [15815209.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Hepatology. 1997 Oct;26(4):891-5 [9328310.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):455-8 [8945470.001]
  • [Cites] Cell. 1996 Feb 23;84(4):575-85 [8598044.001]
  • [Cites] Arch Surg. 1994 Jul;129(7):712-7 [7517661.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):456-62 [2813344.001]
  • [Cites] Gastroenterology. 1985 Nov;89(5):1132-8 [2412930.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):463-80 [15062656.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1323-9 [15131793.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1470-5 [14598263.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):312-5 [12355088.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):927-35 [12297840.001]
  • [Cites] Hepatology. 2007 Sep;46(3):740-8 [17663417.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1435-41 [16949914.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14437-46 [17379603.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):74-81 [10636105.001]
  • (PMID = 19669260.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716879
  •  go-up   go-down


51. Shuhaiber JH: Evaluating the quality of trials of hypothermic circulatory arrest aortic surgery. Asian Cardiovasc Thorac Ann; 2007 Oct;15(5):449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating the quality of trials of hypothermic circulatory arrest aortic surgery.
  • The quality of level 1 evidence in reports on deep hypothermic circulatory arrest was assessed, and the confounding factors in surgical management and study design that can prevent meta-analysis formulation were determined.
  • A systematic search of the literature was conducted using categorized nomenclature for randomized controlled trials in adult patients undergoing deep hypothermic circulatory arrest in the last 40 years.
  • Twelve randomized controlled trials (2.3%) were found among 504 publications on deep hypothermic circulatory arrest listed on Medline from 1960; only 4 of them related to adults.
  • One adequately powered study demonstrated reduced blood loss in deep hypothermic circulatory arrest using aprotinin.
  • Existing studies of deep hypothermic circulatory arrest are insufficient and inconsistent in the outcome measured, which explains the lack of a meta-analysis.
  • [MeSH-major] Aortic Diseases / surgery. Cerebrovascular Disorders / etiology. Circulatory Arrest, Deep Hypothermia Induced / adverse effects. Meta-Analysis as Topic. Randomized Controlled Trials as Topic / standards. Vascular Surgical Procedures

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17911080.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


52. Peltz M, Sandoval BA, Jessen ME: Traumatic rupture of a descending thoracic aortic homograft. Ann Thorac Surg; 2005 Aug;80(2):710-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The injury was successfully repaired with a Dacron graft by using hypothermic circulatory arrest.
  • [MeSH-minor] Accidents, Traffic. Adolescent. Aneurysm, False / diagnosis. Aneurysm, False / surgery. Blood Vessel Prosthesis Implantation. Female. Humans. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039236.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Gargano JW, Holzman C, Senagore P, Thorsen P, Skogstrand K, Hougaard DM, Rahbar MH, Chung H: Mid-pregnancy circulating cytokine levels, histologic chorioamnionitis and spontaneous preterm birth. J Reprod Immunol; 2008 Oct;79(1):100-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some spontaneous preterm deliveries (PTD) are caused by occult infections of the fetal membranes (histologic chorioamnionitis [HCA]).
  • High levels of infection-related markers, including some cytokines, sampled from maternal circulation in mid-pregnancy have been linked to PTD, but whether these specifically identify HCA has not been established.
  • We have tested associations between 13 Th1, Th2 and Th17 cytokines and PTD with and without HCA in a prospective cohort study.
  • A panel of cytokines was assessed using a multiplex assay in maternal plasma collected at 15-27 weeks of gestation.
  • Severe HCA was scored by a placental pathologist blinded to clinical variables.
  • Multivariable polytomous logistic regression was used to estimate adjusted odds ratios (OR) per 1 standard deviation (S.D.) increase in cytokine levels using a 5 level outcome variable: PTD <35 weeks with HCA, PTD <35 weeks without HCA, PTD 35-36 weeks with HCA, PTD 35-36 weeks without HCA, and term (referent).
  • Interleukin (IL)-1beta, IL-2, IL-12, interferon-gamma, IL-4, IL-6 and transforming growth factor-beta were all significantly associated with PTD <35 weeks with HCA, with ORs of 1.6-2.3 per S.D. increase.
  • None of these were associated with PTD <35 weeks without HCA or PTD 35-36 weeks with HCA.
  • Although the tissues of origin of circulating cytokines are unclear, the observed elevations across many cytokines among women who later delivered <35 weeks with HCA may represent a robust immune response to infection within gestational tissues.
  • These results suggest that women with HCA could be identified using relatively non-invasive means.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Preterm Labor.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Reprod Immunol. 2007 Oct;75(2):133-40 [17442403.001]
  • [Cites] Am J Epidemiol. 2007 Oct 1;166(7):786-94 [17625222.001]
  • [Cites] Lancet. 2008 Jan 19;371(9608):261-9 [18207020.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Feb;34(1):7-11 [18226122.001]
  • [Cites] Semin Immunol. 2007 Dec;19(6):362-71 [18035554.001]
  • [Cites] Am J Obstet Gynecol. 2000 Mar;182(3):625-30 [10739519.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Jul;15 Suppl 2:136-58 [11520406.001]
  • [Cites] BJOG. 2002 May;109(5):534-9 [12066943.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Oct;16(4):297-304 [12445145.001]
  • [Cites] Clin Biochem. 2003 Jul;36(5):323-31 [12849862.001]
  • [Cites] J Reprod Immunol. 2003 Aug;59(2):161-73 [12896820.001]
  • [Cites] Am J Obstet Gynecol. 2003 Aug;189(2):560-7 [14520234.001]
  • [Cites] Int Arch Allergy Immunol. 2004 Jun;134(2):93-119 [15153791.001]
  • [Cites] Am J Clin Nutr. 1987 Nov;46(5):736-48 [3314468.001]
  • [Cites] Am J Obstet Gynecol. 1993 Oct;169(4):1035-44 [8238116.001]
  • [Cites] Obstet Gynecol. 1996 Mar;87(3):360-5 [8598955.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 1):656-60 [8677062.001]
  • [Cites] Am J Obstet Gynecol. 1996 Nov;175(5):1356-9 [8942514.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):465-9 [9277663.001]
  • [Cites] Am J Obstet Gynecol. 1998 Mar;178(3):546-50 [9539524.001]
  • [Cites] J Perinat Med. 1998;26(1):17-26 [9595363.001]
  • [Cites] Lancet. 1999 Sep 25;354(9184):1095-6 [10509506.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1854-66 [16081507.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Oct 1;122(2):136-43 [15893871.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1108-13 [16236995.001]
  • [Cites] Matern Child Health J. 2006 Mar;10(2):127-38 [16400535.001]
  • [Cites] Nat Immunol. 2006 Jun;7(6):557-9 [16715066.001]
  • [Cites] Immunity. 2006 Jun;24(6):677-88 [16782025.001]
  • [Cites] Semin Fetal Neonatal Med. 2006 Oct;11(5):317-26 [16839830.001]
  • [Cites] Trends Immunol. 2006 Aug;27(8):358-61 [16793343.001]
  • [Cites] Obstet Gynecol. 2007 Jan;109(1):121-7 [17197597.001]
  • [Cites] J Reprod Immunol. 2007 Feb;73(1):74-84 [17034864.001]
  • [Cites] Clin Biochem. 2007 Mar;40(5-6):330-5 [17289011.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):969-75 [17192290.001]
  • [Cites] J Reprod Immunol. 2007 Apr;73(2):158-65 [17074396.001]
  • [Cites] Mol Aspects Med. 2007 Apr;28(2):192-209 [17433431.001]
  • [Cites] Am J Epidemiol. 2007 Aug 1;166(3):323-31 [17504778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12099-104 [17623780.001]
  • [Cites] Acta Obstet Gynecol Scand. 2007;86(9):1103-10 [17712652.001]
  • [Cites] Am J Epidemiol. 2007 Dec 1;166(11):1312-9 [17906337.001]
  • (PMID = 18814919.001).
  • [ISSN] 0165-0378
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD34543; United States / NICHD NIH HHS / HD / HD034543-05A1; United States / NICHD NIH HHS / HD / HD034543-07S1; United States / NICHD NIH HHS / HD / HD034543-08; United States / NCCDPHP CDC HHS / DP / U01 DP000143-01; United States / NICHD NIH HHS / HD / R01 HD034543-07; United States / NICHD NIH HHS / HD / R01 HD034543; United States / NICHD NIH HHS / HD / R01 HD034543-04; United States / NICHD NIH HHS / HD / R01 HD034543-06; United States / NICHD NIH HHS / HD / R01 HD034543-03; United States / NICHD NIH HHS / HD / R01 HD034543-05A1; United States / NICHD NIH HHS / HD / HD034543-06; United States / NCCDPHP CDC HHS / DP / U01 DP000143; United States / NICHD NIH HHS / HD / HD034543-03; United States / NICHD NIH HHS / HD / R01 HD034543-08; United States / NICHD NIH HHS / HD / R01 HD034543-07S1; United States / NICHD NIH HHS / HD / HD034543-04; United States / NICHD NIH HHS / HD / HD034543-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS77538; NLM/ PMC2683663
  •  go-up   go-down


54. Wellen JR, Anderson CD, Doyle M, Shenoy S, Nadler M, Turmelle Y, Shepherd R, Chapman WC, Lowell JA: The role of liver transplantation for hepatic adenomatosis in the pediatric population: case report and review of the literature. Pediatr Transplant; 2010 May;14(3):E16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liver transplantation for hepatic adenomatosis in the pediatric population: case report and review of the literature.
  • Hepatic adenomas are benign lesions often found in young women during childbearing age.
  • These tumors are often solitary but can also be multiple in which case this is referred to as hepatic adenomatosis (HA).
  • HA is defined as having greater than or equal to ten adenomas within an otherwise normal liver.
  • We present a case of a teenager with HA who underwent an orthotopic liver transplant for complications of her HA.
  • To date there are only four reports of teenagers, without an underlying glycogen storage disease, who have undergone a liver transplant for HA.
  • Liver transplantation within the pediatric population is an acceptable treatment for HA that are deemed unresectable.
  • [MeSH-major] Adenoma, Liver Cell / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Biopsy. Female. Humans. Liver Function Tests


55. Urbanski PP, Lenos A, Lindemann Y, Zacher M, Frank S, Diegeler A: Use of a carotid artery for arterial cannulation: side-related differences. Thorac Cardiovasc Surg; 2010 Aug;58(5):276-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The arterial line was also used for unilateral cerebral perfusion for brain protection during mild hypothermic circulatory arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • [CommentIn] Thorac Cardiovasc Surg. 2010 Dec;58(8):503; author reply 504 [21110280.001]
  • (PMID = 20680903.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Raszeja-Wyszomirska J, Wasilewicz MP, Zasada-Cedro K, Golanowska M, Wiechowska-Kozłowska A: [Benign solid tumors of the liver--review of current knowledge]. Pol Merkur Lekarski; 2009 Jul;27(157):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign solid tumors of the liver--review of current knowledge].
  • Benign solid tumors of the liver may be one of the great diagnostic difficulties among the hepatic problems.
  • The most common of them are: haemangiomas, adenomas, nodular regenerative hyperplasia (NRH) and focal nodular hyperplasia (FNH).
  • This article presents a summary of the main information on benign solid tumors of the liver based on internet database MEDLINE.
  • Also, it contains some proceedings of treatment and control for patients with those lesions, which can help to differentiate benign and malignant hepatic tumors.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / pathology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / therapy. Diagnosis, Differential. Diagnostic Imaging / methods. Hemangioma / diagnosis. Hemangioma / therapy. Humans. Hyperplasia. Liver Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650434.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 39
  •  go-up   go-down


57. Jain D, Sharma MC, Sarkar C, Suri V, Garg A, Mahapatra AK, Kumar L: Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case. J Neurooncol; 2008 Jun;88(2):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case.
  • The authors report an unusual case of hepatosplenic T-cell lymphoma in a 41-year-old male patient.
  • Liver was also infiltrated with similar cells.
  • A provisional diagnosis of hairy cell leukemia was made.
  • Subsequently, after 6 months he was found to have a sellar mass, which on microscopy revealed lymphoma cells.
  • These cells were positive for leukocyte common antigen and T-cell markers.
  • Finally, based on overall clinical, histomorphological and immunophenotypic features, a diagnosis of hepatosplenic T-cell lymphoma, possibly gamma delta type, involving pituitary gland was established.
  • On follow up, this patient showed evidence of bone marrow involvement and died after 1.5-year of diagnosis.
  • [MeSH-major] Liver Neoplasms / complications. Lymphoma, T-Cell / metabolism. Pituitary Gland / pathology. Pituitary Neoplasms / etiology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Splenic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):311-6 [10090680.001]
  • [Cites] Neurology. 1993 Aug;43(8):1591-3 [8394522.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4567-75 [11600505.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4261-9 [12907441.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1134-7 [17204179.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leukemia. 2000 Jun;14(6):991-7 [10865963.001]
  • [Cites] Ann Hematol. 1992 Sep;65(3):111-5 [1391120.001]
  • [Cites] Clin Infect Dis. 1997 Mar;24(3):291-300; quiz 301-2 [9114175.001]
  • [Cites] Pituitary. 2005;8(2):139-46 [16379034.001]
  • [Cites] J Neurosurg. 1990 Aug;73(2):206-11 [2366078.001]
  • [Cites] Blood. 2003 May 1;101(9):3407-12 [12522013.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] J R Soc Med. 1997 May;90(5):274-5 [9204025.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):102-5 [8558135.001]
  • [Cites] J Immunol. 1991 Jun 15;146(12):4421-6 [1710251.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Oct;49(4):441-5 [9876340.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):781-90 [9236834.001]
  • [Cites] Int J Clin Pract. 1998 Oct;52(7):513-4 [10622097.001]
  • [Cites] No Shinkei Geka. 1998 Jan;26(1):53-8 [9488992.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1947-50 [15223661.001]
  • [Cites] J Med Invest. 1998 Feb;44(3-4):215-7 [9597812.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):41-50 [11447750.001]
  • [Cites] N Engl J Med. 1991 Oct 10;325(15):1078-81 [1832485.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):1027-32 [10895827.001]
  • (PMID = 18317685.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


58. Musch MW, Arvans DL, Wu GD, Chang EB: Functional coupling of the downregulated in adenoma Cl-/base exchanger DRA and the apical Na+/H+ exchangers NHE2 and NHE3. Am J Physiol Gastrointest Liver Physiol; 2009 Feb;296(2):G202-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional coupling of the downregulated in adenoma Cl-/base exchanger DRA and the apical Na+/H+ exchangers NHE2 and NHE3.
  • Non-nutrient-dependent salt absorption across the brush-border membrane of intestinal epithelial cells is primarily mediated by coupled apical Na(+)/H(+) (aNHE) and anion exchange transport, with the latter suspected of being mediated by DRA (downregulated in adenoma; SLC26A3) that is defective in congenital chloridorrhea.
  • To investigate DRA in greater detail and determine whether DRA and NHE activities can be coupled, we measured (22)Na(+) and (36)Cl(-) uptake in Caco2BBE colon cells infected with the tet-off-inducible DRA transgene.
  • Under basal conditions, DRA activity was low in normal and infected Caco2BBE cells in the presence of tetracycline, whereas NHE activities could be easily detected.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHAZOLAMIDE .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37551-8 [10608808.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G923-34 [17761837.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Nov;279(5):G931-42 [11052990.001]
  • [Cites] Genomics. 2000 Nov 15;70(1):102-12 [11087667.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 9;1511(1):17-27 [11248201.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 May;280(5):C1224-32 [11287336.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26906-15 [11328806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9425-30 [11459928.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15191-6 [11734628.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):709-24 [11875004.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G776-84 [11960774.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33963-7 [12119287.001]
  • [Cites] Biochim Biophys Acta. 2002 Nov 14;1573(2):141-8 [12399023.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Mar;284(3):C769-79 [12444019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1943-8 [12576544.001]
  • [Cites] J Clin Invest. 2003 Apr;111(7):931-43 [12671039.001]
  • [Cites] J Physiol. 2003 May 15;549(Pt 1):3-19 [12651923.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 May;286(5):C1062-70 [15075205.001]
  • [Cites] J Clin Invest. 1970 Mar;49(3):557-67 [5415682.001]
  • [Cites] Am J Physiol. 1971 May;220(5):1388-96 [5574657.001]
  • [Cites] J Clin Invest. 1972 Aug;51(8):1958-68 [5054457.001]
  • [Cites] Am J Physiol. 1984 May;246(5 Pt 1):G603-10 [6426321.001]
  • [Cites] Am J Physiol. 1985 Aug;249(2 Pt 1):G236-45 [3927745.001]
  • [Cites] Am J Physiol. 1991 Sep;261(3 Pt 2):F452-8 [1909498.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4166-70 [7683425.001]
  • [Cites] J Cell Sci. 1993 Jun;105 ( Pt 2):445-60 [8408276.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):106-13 [8282777.001]
  • [Cites] Surgery. 1994 Aug;116(2):388-94; discussion 394-5 [8048004.001]
  • [Cites] Am J Physiol. 1996 Aug;271(2 Pt 1):G330-7 [8770049.001]
  • [Cites] Am J Physiol. 1996 Jan;270(1 Pt 1):G29-41 [8772498.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):316-9 [8896562.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):C1261-72 [9612213.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 1):C693-701 [9730953.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 1):G185-92 [9886994.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22855-61 [10428871.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):G321-32 [10444446.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24753-8 [10455146.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1140-9 [15284023.001]
  • [Cites] Pflugers Arch. 2005 Feb;449(5):479-90 [15480750.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Apr;288(4):C957-65 [15574486.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2499-511 [15990874.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G719-28 [16373425.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37962-71 [17001077.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1079-88 [17170027.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1549-58 [17307723.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Mar;278(3):G409-15 [10712260.001]
  • (PMID = 19056765.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-38510; United States / NIDDK NIH HHS / DK / DK-42086
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiporters; 0 / Chloride-Bicarbonate Antiporters; 0 / Chlorides; 0 / Clathrin; 0 / RNA, Messenger; 0 / SLC26A3 protein, human; 0 / SLC9A2 protein, human; 0 / Sodium Radioisotopes; 0 / Sodium-Hydrogen Antiporter; 0 / Synaptotagmin I; 0 / sodium-hydrogen exchanger 3; 1214-79-5 / 5-dimethylamiloride; 4U5MP5IUD8 / Niflumic Acid; 7DZO8EB0Z3 / Amiloride; 9NEZ333N27 / Sodium; E0399OZS9N / Cyclic AMP; Q1O6DSW23R / 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; SY7Q814VUP / Calcium; W733B0S9SD / Methazolamide
  • [Other-IDs] NLM/ PMC2643907
  •  go-up   go-down


59. Saczewski F, Innocenti A, Brzozowski Z, Slawiński J, Pomarnacka E, Kornicka A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides. J Enzyme Inhib Med Chem; 2006 Oct;21(5):563-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These derivatives were medium potency hCA I inhibitors (K(I)s in the range of 1.5-5.7 microM), two derivatives were strong hCA II inhibitors (K(I)s in the range of 15-16 nM), whereas the others showed weak activity.
  • These compounds inhibited hCA IX with inhibition constants in the range 160-1950 nM and hCA XII with inhibition constants in the range 1.2-413 nM.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194028.001).
  • [ISSN] 1475-6366
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Isoenzymes; 0 / Sulfonamides
  •  go-up   go-down


60. Ferrucci LM, Cross AJ, Graubard BI, Brinton LA, McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R: Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Br J Cancer; 2009 Jul 7;101(1):178-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Comparing the fifth to the first quintile, red meat (HR=1.23; 95% CI=1.00-1.51, P trend=0.22), the heterocyclic amine (HCA), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), (HR=1.26; 95% CI=1.03-1.55; P trend=0.12), and dietary iron (HR=1.25; 95% CI=1.02-1.52; P trend=0.03) were positively associated with breast cancer.
  • We observed elevated, though not statistically significant, risks with processed meat, the HCA 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx), mutagenic activity, iron from meat, and haem iron from meat.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):260-3 [11146455.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):905-10 [11008907.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):839-49 [11375754.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Int J Epidemiol. 2002 Feb;31(1):78-85 [11914299.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):801-8 [12223422.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:145-52 [12351154.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):221-7 [12569578.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):19-27 [12708721.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1672-85 [14583769.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):153-71 [14643418.001]
  • [Cites] Nutr Cancer. 2003;46(2):131-7 [14690788.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):205-12 [14973098.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):295-303 [15090724.001]
  • [Cites] J Am Diet Assoc. 1982 Apr;80(4):307-11 [7061776.001]
  • [Cites] Carcinogenesis. 1991 Jan;12(1):111-4 [1988169.001]
  • [Cites] Crit Rev Food Sci Nutr. 1992;31(4):333-67 [1581009.001]
  • [Cites] Carcinogenesis. 1995 Feb;16(2):431-4 [7859378.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):140-4 [8567108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):573-81 [9264269.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1757-62 [9328172.001]
  • [Cites] J Epidemiol Community Health. 1998 Feb;52(2):105-10 [9578857.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 18;90(22):1724-9 [9827527.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):13-7 [9935222.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):233-9 [10090301.001]
  • [Cites] Mol Nutr Food Res. 2005 Jul;49(7):648-55 [15986387.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):717-25 [16614114.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2253-9 [17101944.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1139-46 [17406351.001]
  • [Cites] Epidemiology. 2007 May;18(3):373-82 [17435448.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1306-8 [17548704.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1784-94 [17726138.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1047-53 [17823849.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(1):123-32 [17431764.001]
  • [Cites] Eur J Cancer Prev. 2008 Feb;17(1):39-47 [18090909.001]
  • [Cites] Nutr Cancer. 2008;60(3):313-24 [18444165.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1637-43 [18636564.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2146-51 [18669582.001]
  • [Cites] Nutr Cancer. 2009;61(1):36-46 [19116874.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2430-5 [19165862.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):607-15 [10753193.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1352-4 [10944558.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • (PMID = 19513076.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA105666-01; United States / NCI NIH HHS / CA / TU2 CA105666; United States / Intramural NIH HHS / / Z01 CP010127-12; United States / NCI NIH HHS / CA / TU2 CA105666-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron, Dietary; 0 / Mutagens
  • [Other-IDs] NLM/ PMC2713710
  •  go-up   go-down


61. Seike M, Kondo T, Fujii K, Okano T, Yamada T, Matsuno Y, Gemma A, Kudoh S, Hirohashi S: Proteomic signatures for histological types of lung cancer. Proteomics; 2005 Jul;5(11):2939-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed proteomic studies on lung cancer cells to elucidate the mechanisms that determine histological phenotype.
  • Thirty lung cancer cell lines with three different histological backgrounds (squamous cell carcinoma, small cell lung carcinoma and adenocarcinoma) were subjected to two-dimensional difference gel electrophoresis (2-D DIGE) and grouped by multivariate analyses on the basis of their protein expression profiles.
  • We found that hierarchical clustering analysis and principal component analysis divided the cell lines according to their original histology.
  • Spot ranking analysis using a support vector machine algorithm and unsupervised classification methods identified 32 protein spots essential for the classification.
  • Next, lung cancer cells isolated from tumor tissue by laser microdissection were classified on the basis of the expression pattern of these 32 protein spots.
  • Based on the expression profile of the 32 spots, the isolated cancer cells were categorized into three histological groups: the squamous cell carcinoma group, the adenocarcinoma group, and a group of carcinomas with other histological types.
  • In conclusion, our results demonstrate the utility of quantitative proteomic analysis for molecular diagnosis and classification of lung cancer cells.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lung / chemistry. Lung Neoplasms / pathology. Neoplasm Proteins / analysis
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Small Cell / pathology. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Humans. Microdissection. Multivariate Analysis. Peptide Mapping

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996008.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


62. Ikota H, Kinjo S, Yokoo H, Nakazato Y: Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol; 2006 May;111(5):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used hierarchical clustering analysis to interpret these data, which resulted in separation of all the brain tumors into seven groups.
  • Although there were some exceptions, cases with the same histological diagnosis were generally grouped together.
  • We then carried out statistical analyses to find the most useful antibodies for grouping of brain tumors.
  • Six antibodies [EMA, AE1/AE3, TUJ1, nestin, neurofilament protein-MH (NF-MH) and perivascular cells GP-1] showed significant differences between high-grade and low-grade gliomas.
  • [MeSH-major] Antibodies / immunology. Astrocytoma / immunology. Brain Neoplasms / immunology. Immunohistochemistry / methods. Oligodendroglioma / immunology. Protein Array Analysis / methods
  • [MeSH-minor] Aquaporin 4 / immunology. Aquaporin 4 / metabolism. Basic Helix-Loop-Helix Transcription Factors / immunology. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Cluster Analysis. Diagnosis, Differential. Glial Fibrillary Acidic Protein / immunology. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / immunology. Intermediate Filament Proteins / metabolism. Mucin-1 / immunology. Mucin-1 / metabolism. Nerve Tissue Proteins / immunology. Nerve Tissue Proteins / metabolism. Nestin. Prognosis. Vimentin / immunology. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598485.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Antibodies; 0 / Aquaporin 4; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Mucin-1; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Vimentin; 0 / alpha-internexin
  •  go-up   go-down


63. Chia WK, Sharifah NA, Reena RM, Zubaidah Z, Clarence-Ko CH, Rohaizak M, Naqiyah I, Srijit D, Hisham AN, Asmiati A, Rafie MK: Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms. Cancer Genet Cytogenet; 2010 Jan 1;196(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms.
  • At the present time, the differentiation between follicular thyroid carcinoma (FTC) and adenoma can be made only postoperatively and is based on the presence of capsular or vascular invasion.
  • The ability to differentiate preoperatively between the malignant and benign forms of follicular thyroid tumors assumes greater importance in any clinical setting.
  • In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization.
  • In addition, 2/18 (11.1%) FTC and 1/5 (20%) HCA showed 3p25 aneusomy only.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963130.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


64. Bioulac-Sage P, Balabaud C, Zucman-Rossi J: [Interest of immunohistochemistry for the diagnosis of benign hepatocellular tumors]. Ann Pathol; 2010 Dec;30(6):439-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interest of immunohistochemistry for the diagnosis of benign hepatocellular tumors].
  • [Transliterated title] Apport de l'immunohistochimie dans le diagnostic des tumeurs hépatocellulaires bénignes.
  • In this review, we focus on the interest of immunohistochemistry first, to differentiate the two types of benign hepatocellular nodules: focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) and second, to recognize the different subtypes of HCA: HNF1α inactivated HCA, β-catenin activated HCA and inflammatory HCA.
  • Immunohistochemical characteristics described on resected specimen are suitable on biopies of these tumors, facilitating their diagnosis and therefore allowing a better management of the patients.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / analysis. Focal Nodular Hyperplasia / diagnosis. Immunohistochemistry. Liver Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Glutamate-Ammonia Ligase / analysis. Glutamate-Ammonia Ligase / physiology. Hepatocyte Nuclear Factor 1-alpha / analysis. Hepatocyte Nuclear Factor 1-alpha / genetics. Hepatocyte Nuclear Factor 1-alpha / physiology. Humans. Inflammation. beta Catenin / analysis. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21167430.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / HNF1A protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / beta Catenin; EC 6.3.1.2 / Glutamate-Ammonia Ligase
  •  go-up   go-down


65. Waalkes MP, Liu J, Ward JM, Diwan BA: Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol Appl Pharmacol; 2006 Sep 15;215(3):295-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen.
  • Arsenic alone increased hepatocellular carcinoma (14%), adenoma (23%) and total tumors (31%) compared to control (0, 2 and 2%, respectively).
  • Arsenic alone also increased lung adenocarcinoma, adrenal cortical adenoma and renal cystic tubular hyperplasia compared to control.
  • Compared to arsenic alone, arsenic plus DES increased liver tumor incidence in mice at risk 2.2-fold and increased liver tumor multiplicity (tumors/liver) 1.8-fold.
  • The treatments alone did not impact urinary bladder carcinogenesis, but arsenic plus TAM significantly increased formation of urinary bladder transitional cell tumors (papilloma and carcinoma; 13%) compared to control (0%).
  • Urinary bladder lesions and hepatocellular carcinoma induced by arsenic plus TAM and/or DES overexpressed estrogen receptor-alpha, indicating that aberrant estrogen signaling may have been a factor in the enhanced carcinogenic response.
  • Thus, in male CD1 mice, gestational arsenic exposure alone induced liver adenoma and carcinoma, lung adenocarcinoma, adrenal adenoma and renal cystic hyperplasia.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Liver Neoplasms / etiology. Tamoxifen / toxicity. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712894.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens, Non-Steroidal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


66. Davis RA, Innocenti A, Poulsen SA, Supuran CT: Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. Bioorg Med Chem; 2010 Jan 1;18(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated the enzyme inhibition characteristics of a natural product (NP)-based phenolic library against a panel of human carbonic anhydrases (hCAs, EC 4.2.1.1) which included hCAs I and II (cytosolic) and hCA VA/VB (mitochondrial isoforms).
  • Most of these compounds were weak, micromolar inhibitors of the two cytosolic hCAs (K(I)s >10 microM) but showed good hCA VA/VB inhibitory activity with inhibition constants in the range of 70-125 nM.
  • The selectivity ratios for inhibiting the mitochondrial over the cytosolic isoforms for these phenol derivatives were in the range of 120-3800, making them the most isoform-selective compounds for inhibiting hCA VA/VB known to date.
  • Thus the NP inhibitors identified during these studies are excellent leads for obtaining even more effective compounds that selectively target mitochondrial hCAs, and also have the potential to be used as tools for understanding the physiological processes that are regulated by the two mitochondrial CA isoforms.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19962903.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Isoenzymes; 0 / Phenols; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


67. Mehrabi M, Ghobadi S, Khodarahmi R: Spectroscopic study on the interaction of celecoxib with human carbonic anhydrase II: thermodynamic characterization of the binding process. J Photochem Photobiol B; 2009 Dec 2;97(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of celecoxib, a sulfonamide drug, on the structure and function of human carbonic anhydrase II (hCA II) was investigated by various spectroscopic techniques such as UV-Vis, fluorescence and circular dichroism (CD) spectroscopy and differential scanning calorimetry (DSC), in 20 mM Tris, pH 7.75 at 27 degrees C.
  • Kinetic results revealed that celecoxib inhibits the esterase activity of hCA II in a linear competitive manner with K(i) = 61.61 + or -3.05 nM.
  • Stern-Volmer analysis of quenching data at different temperatures elucidated that the quenching of intrinsic fluorescence of hCA II is occurred through a static quenching mechanism.
  • Analysis of the thermodynamic parameters of binding showed that hydrogen bonding and hydrophobic interactions play the major role in stabilization of the enzyme-drug complex.
  • The Job's plot confirmed the existence of one binding site for celecoxib in hCA II.
  • The far- and near-UV CD experiments indicated that celecoxib causes a little increment in alpha-helicity content of hCA II whereas its flexibility is decreased somewhat upon celecoxib binding.

  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Photochem Photobiol B. 2010 Mar 8;98(3):225
  • (PMID = 19879770.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anilino Naphthalenesulfonates; 0 / Cyclooxygenase 2 Inhibitors; 0 / Fluorescent Dyes; 0 / Pyrazoles; 0 / Sulfonamides; 82-76-8 / 1-anilino-8-naphthalenesulfonate; EC 4.2.1.- / Carbonic Anhydrase II; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


68. Brennan G, McSherry R: Exploring the transition and professional socialisation from health care assistant to student nurse. Nurse Educ Pract; 2007 Jul;7(4):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Minimal research is available examining the socialisation process from the perspective of students with health care knowledge who prior to undertaking their training worked as a health care assistant (HCA).
  • OBJECTIVE: The studies aim was to determine the transitional processes associated with moving from a HCA to Student Nurse.
  • POPULATION, SAMPLE, SETTING: A homogeneous sample of 14 students with previous experience as a HCA within the field of adult nursing was used.
  • ] thematic content analysis.
  • Equally a new concept is introduced from the findings, that of 'the comfort zone', which explores the intentional reversal into the HCA role by the participants of the study.
  • From the findings a framework for the transition and professional socialisation from HCA to student nurse is provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689446.001).
  • [ISSN] 1873-5223
  • [Journal-full-title] Nurse education in practice
  • [ISO-abbreviation] Nurse Educ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. He F, Lin L, Zhao S, Zhao S, Chen S, Wang X: [Fast formation of biomimetic apatite coatings on pure porous titanium implant's surface]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Aug;24(4):806-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A thin calcium-phosphate coating was deposited on all the specimens of the two groups, the surface consisted of well-formed crystals, which were proved to be the mixture of hydroxycarbonated apatite (HCA) and octacalcium phosphate (OCP); the coating's Ca/P rate was 1.51.

  • Hazardous Substances Data Bank. TITANIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899750.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Coated Materials, Biocompatible; D1JT611TNE / Titanium
  •  go-up   go-down


70. Loewy EH: Age discrimination at its best: should chronological age be a prime factour in medical decision making? Health Care Anal; 2005 Jun;13(2):101-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper briefly reviews the papers in this special section of HCA and makes the point--a point which should be obvious--that statistics are useful only as guidelines but tell one nothing about the individual patient in front of you.
  • It is pointed out that what matters is a patient's disease and not his/her age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16013524.001).
  • [ISSN] 1065-3058
  • [Journal-full-title] Health care analysis : HCA : journal of health philosophy and policy
  • [ISO-abbreviation] Health Care Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] KIE/ 123470
  • [Keywords] KIE ; Analytical Approach / Health Care and Public Health
  • [General-notes] KIE/ 20 fn.; KIE/ KIE Bib: patien care/aged; resource allocation; selection for treatment
  •  go-up   go-down


71. Carestiato FN, Silva KC, Dimetz T, Oliveira LH, Cavalcanti SM: Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz J Infect Dis; 2006 Oct;10(5):331-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay.
  • Recently developed, the second generation of the hybrid capture test (HCA II) is a non-radioactive, relatively rapid, hybridization assay, designed to detect 18 HPV types divided into high and low-risk groups.
  • We evaluated 7,314 patients (5,833 women and 1,481 men) for HPV infection by HCA II.
  • Because of high costs, the HCA II test cannot be recommended for routine mass screening for cervical infection in poor countries.
  • These findings point to the need for close and careful management of patients, thereby reducing overtreatment, allowing analysis of both sexual partners and finally contributing to the control of genital infections associated with a risk for cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil / epidemiology. Child. DNA, Viral / analysis. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17293921.001).
  • [ISSN] 1413-8670
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


72. Tustian W: Allowing HCAs to develop is good for patients and nurses. Nurs Stand; 2006 Sep 20;21(2):30-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allowing HCAs to develop is good for patients and nurses.
  • As a former HCA about to begin my second year of nurse training, I was disappointed to read David Salvage's views on caring responsibilities (reflections August 30).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28086506.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Ananiadou OG, Drossos GE, Bibou KN, Palatianos GM, Johnson EO: Acute regional neuronal injury following hypothermic circulatory arrest in a porcine model. Interact Cardiovasc Thorac Surg; 2005 Dec;4(6):597-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute regional neuronal injury following hypothermic circulatory arrest in a porcine model.
  • OBJECTIVES: Although deep hypothermic circulatory arrest (HCA) is routinely used to interrupt normal perfusion of the brain and prevent subsequent cerebral ischemic injury during cardiac surgery, it is associated with various forms of neurologic disturbances.
  • Neurologic sequelae after prolonged HCA include motor, memory and cognitive deficits.
  • The present study was designed to assess acute regional neuronal injury after HCA in an animal model.
  • METHODS: Six piglets underwent 75 min of HCA at 18 degrees C.
  • Regional patterns of neuronal apoptosis after HCA was characterized by in situ DNA fragmentation using terminal deoxyneucleotidyl-transferase-mediated biotin-dUTP nick end-labeling (TUNEL) histochemistry.
  • Hematoxylin and eosin histology was used to characterize cell damage morphologically.
  • TUNEL-positive cells were scored on a scale of 0 to 5.
  • Grade 0: no TUNEL-positive cells; Grade 1: <10%, Grade 2: 10-25%, Grade 3: 25-50%, Grade 4: 50-75%; and Grade 5: >75%.
  • RESULTS: TUNEL-positive cells indicating DNA-fragmentation were scored in the precentral gyrus (motor neocortex), postcentral gyrus (sensory neocortex), hippocampus, cerebellum, thalamus and ventral medulla of HCA treated animals and were significantly greater than in normal controls (P<or=0.05).
  • Significantly higher concentrations of TUNEL-positive cells were observed in the sensory and motor neocortex and hippocampus, compared to the cerebellum, thalamus and medulla, indicating an increased selective vulnerability of these brain subregions (P<or=0.05).
  • Despite significant DNA fragmentation indicated by high-concentrations TUNEL-positive cells, no morphologic evidence of apoptosis or necrosis was observed in this acute model.
  • CONCLUSION: The data indicate that sensory and motor neocortex and hippocampal neurons are selectively vulnerable to neurologic injury after HCA as indicated by elevated levels of TUNEL-positive cells in these brain regions.
  • The absence of morphological evidence of apoptosis or necrosis with high levels of TUNEL-positive cells, strongly suggests activation of the apoptotic mechanisms at this early stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670490.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Larsen BT, Bubolz AH, Mendoza SA, Pritchard KA Jr, Gutterman DD: Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species. Arterioscler Thromb Vasc Biol; 2009 May;29(5):739-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hydrogen peroxide (H2O2) is an endothelium-derived hyperpolarizing factor in human coronary arterioles (HCAs).
  • Superoxide and H2O2 production was assayed in HCAs and human coronary artery endothelial cells (HCAECs) using dihydroethidium and dichlorodihydrofluorescein histofluorescence, respectively.
  • Diameter changes of HCAs were measured by videomicroscopy.
  • NADPH oxidase subunits Nox1, Nox2, Nox4, p22, p47, and p67 were each expressed in HCA endothelium.
  • In HCAs or HCAECs incubated with dihydroethidium and dichlorodihydrofluorescein, BK induced superoxide and H2O2 formation, which was inhibited by gp91ds-tat or apocynin but not by gp91scram-tat or rotenone.
  • HPLC analysis confirmed that BK specifically induced superoxide production.
  • CONCLUSION: We conclude that endothelial NADPH oxidase is a functionally relevant source of H2O2 that mediates agonist-induced dilation in the human heart.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2000 Aug;36(2):270-5 [10948089.001]
  • [Cites] J Clin Invest. 2000 Dec;106(12):1521-30 [11120759.001]
  • [Cites] Circ Res. 2001 Jan 19;88(1):44-51 [11139472.001]
  • [Cites] Circulation. 2001 Apr 17;103(15):1992-8 [11306529.001]
  • [Cites] Circ Res. 2001 Aug 31;89(5):408-14 [11532901.001]
  • [Cites] Hypertension. 2001 Nov;38(5):1162-6 [11711515.001]
  • [Cites] Circ Res. 2002 May 17;90(9):1028-36 [12016270.001]
  • [Cites] Eur J Clin Invest. 2002 Oct;32(10):732-7 [12406020.001]
  • [Cites] Hypertension. 2002 Nov;40(5):755-62 [12411473.001]
  • [Cites] Antioxid Redox Signal. 2002 Dec;4(6):899-914 [12573139.001]
  • [Cites] Circ Res. 2003 Feb 7;92(2):e31-40 [12574154.001]
  • [Cites] Free Radic Biol Med. 2003 Jun 1;34(11):1359-68 [12757846.001]
  • [Cites] J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):51-61 [12806586.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Aug;285(2):R277-97 [12855411.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1224-30 [12763764.001]
  • [Cites] Trends Pharmacol Sci. 2003 Sep;24(9):471-8 [12967772.001]
  • [Cites] Circ Res. 2003 Sep 19;93(6):573-80 [12919951.001]
  • [Cites] Pharmacol Rev. 1995 Mar;47(1):25-49 [7784479.001]
  • [Cites] J Clin Invest. 1996 Apr 15;97(8):1916-23 [8621776.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):23317-21 [8798532.001]
  • [Cites] Circulation. 1997 Nov 18;96(10):3570-8 [9396457.001]
  • [Cites] Circulation. 1999 Jun 22;99(24):3132-8 [10377076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5727-32 [15824309.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 May;25(5):995-1001 [15718491.001]
  • [Cites] Cardiovasc Res. 2005 Oct 1;68(1):26-36 [16009356.001]
  • [Cites] Cell Signal. 2006 Jan;18(1):69-82 [15927447.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-9 [16258029.001]
  • [Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1609-19 [16987015.001]
  • [Cites] Trends Pharmacol Sci. 2007 Jan;28(1):32-8 [17150260.001]
  • [Cites] Circ Res. 2008 Jan 4;102(1):59-67 [17975109.001]
  • (PMID = 19213944.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL68769; United States / NHLBI NIH HHS / HL / R01 HL080704; United States / NHLBI NIH HHS / HL / R01 HL080704-04; United States / NHLBI NIH HHS / HL / P01 HL068769; United States / NHLBI NIH HHS / HL / HL080704-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BBX060AN9V / Hydrogen Peroxide; EC 1.6.3.1 / NADPH Oxidase; S8TIM42R2W / Bradykinin
  • [Other-IDs] NLM/ NIHMS126047; NLM/ PMC2727937
  •  go-up   go-down


75. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL: MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol; 2008 Jun;190(6):1534-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR elastography of liver tumors: preliminary results.
  • OBJECTIVE: The purpose of this study was to evaluate the potential value of MR elastography (MRE) in the characterization of solid liver tumors.
  • MATERIALS AND METHODS: Forty-four liver tumors (14 metastatic lesions, 12 hepatocellular carcinomas, nine hemangiomas, five cholangiocarcinomas, three cases of focal nodular hyperplasia, and one hepatic adenoma) were evaluated with MRE.
  • The stiffness value of tumor-free hepatic parenchyma was calculated.
  • Statistical analysis was performed on the stiffness values for differentiation of normal liver, fibrotic liver, benign tumors, and malignant tumors.
  • RESULTS: Malignant liver tumors had significantly greater mean shear stiffness than benign tumors (10.1 kPa vs 2.7 kPa, p < 0.001), fibrotic liver (10.1 kPa vs 5.9 kPa, p < 0.001), and normal liver (10.1 kPa vs 2.3 kPa, p < 0.001).
  • Fibrotic livers had stiffness values overlapping both the benign and the malignant tumors.
  • A cutoff value of 5 kPa accurately differentiated malignant tumors from benign tumors and normal liver parenchyma in this preliminary investigation.
  • CONCLUSION: MR elastography is a promising noninvasive technique for assessing solid liver tumors.
  • Use of MRE may lead to new quantitative tissue characterization parameters for differentiating benign and malignant liver tumors.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):63-71 [11436216.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2 [17916548.001]
  • [Cites] Med Image Anal. 2001 Dec;5(4):237-54 [11731304.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):803-11 [12942086.001]
  • [Cites] Med Image Anal. 2003 Dec;7(4):465-73 [14561551.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1854-7 [7569924.001]
  • [Cites] Radiology. 1996 Mar;198(3):920-6 [8628896.001]
  • [Cites] Nat Med. 1996 May;2(5):601-3 [8616724.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] Magn Reson Imaging. 2005 Feb;23(2):159-65 [15833607.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):173-9 [16521091.001]
  • [Cites] Radiology. 2006 Aug;240(2):440-8 [16864671.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Acta Radiol. 2007 Apr;48(3):327-30 [17453505.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S49-60 [17486052.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 18492904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001981-07; United States / NIBIB NIH HHS / EB / R01 EB001981-08; United States / NIBIB NIH HHS / EB / R01 EB001981; United States / NIBIB NIH HHS / EB / EB001981; United States / NIBIB NIH HHS / EB / R01 EB001981-07; United States / NIBIB NIH HHS / EB / EB001981-08
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS196000; NLM/ PMC2894569
  •  go-up   go-down


76. Gil MV, Calvo LF, Blanco D, Sánchez ME: Assessing the agronomic and environmental effects of the application of cattle manure compost on soil by multivariate methods. Bioresour Technol; 2008 Sep;99(13):5763-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis was used for interpreting data from a pot experiment using samples of three Spanish soils.
  • Hierarchical cluster analysis (HCA) and principal component analysis (PCA) were used; they perfectly differentiated sample groups both as a function of the treatment applied and by sampling date.
  • Multivariate methods may therefore be useful for the analysis and interpretation of a large number of data in soil research.
  • [MeSH-minor] Animals. Cattle. Cluster Analysis. Environmental Monitoring / methods. Multivariate Analysis. Spain

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036814.001).
  • [ISSN] 0960-8524
  • [Journal-full-title] Bioresource technology
  • [ISO-abbreviation] Bioresour. Technol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Manure; 0 / Soil
  •  go-up   go-down


77. Wilmanns C, Steinhauer S, Grossmann J, Ruf G: Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer. Int J Biol Sci; 2009;5(5):458-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose was to develop a metastatic score specific to the hepatic and peritoneal site in colorectal cancer patients from clinical, pathohistological and molecular markers potentially reflecting oncogenic activation (OA) or epithelial-mesenchymal transition (EMT), where OA may reflect an activation and EMT the functional loss of certain genes.
  • The primary tumour stage (OA, EMT), lymphonodal stage (OA), the presence of a lymphangiosis carcinomatosa (OA), histological grade (OA, EMT), and immunoblot extraction of E-cadherin (OA, EMT) were differentially rated with zero to one or two points due to their potential contribution to each process and the resulting scores were validated in 27 colorectal cancer patients (three patients with pre-malignant adenomas, 16 with primaries and two with local recurrencies, three of which were metastatic to the peritoneum, six metastatic to the liver and two metastatic to both, the liver and the peritoneum, and five with hepatic secondaries, one of which at histology was metastatic to the peritoneum too).
  • Median OA and EMT scores, however, were 3.5 and 2 in the case of primaries without further spread, 5 and 4 in those nodal positive, 5 and 4 in the case of peritoneal implants, 6 and 2 in the case of liver metastases, and 6.5 and 3 in the case of a simultaneous hepatic and peritoneal spread, respectively.
  • These differences were significant when scores from patients with and without liver metastases (OA, p<0.002) or with peritoneal implants and isolated hepatic spread (EMT, p<0.01) were compared.
  • [MeSH-major] Carcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary. Severity of Illness Index
  • [MeSH-minor] Adenoma / pathology. Adult. Aged. Cell Transdifferentiation. Colon / pathology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Cell. 2006 Dec 1;127(5):875-7 [17129772.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1027-39 [17129786.001]
  • [Cites] Zentralbl Chir. 2007 Dec;132(6):509-14 [18098078.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6092-9 [18676831.001]
  • [Cites] Cell Cycle. 2009 Jan 15;8(2):284-98 [19177011.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] J Cell Biol. 1998 Jul 13;142(1):85-100 [9660865.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Cell. 1995 Oct 6;83(1):5-8 [7553873.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3827-38 [8508351.001]
  • [Cites] Clin Exp Metastasis. 2004;21(1):75-8 [15065605.001]
  • [Cites] Nature. 2004 Aug 26;430(7003):1034-9 [15329723.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):711-9 [15252840.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6750-6 [11118062.001]
  • [Cites] Hepatology. 2003 Aug;38(2):470-80 [12883492.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6292-8 [1834329.001]
  • (PMID = 19564929.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2702829
  • [Keywords] NOTNLM ; colon cancer / epithelial-mesenchymal transition / metastatic score / oncogenic activation
  •  go-up   go-down


78. Flemming P, Lehmann U, Steinemann D, Kreipe H, Wilkens L: [Hepatocellular adenoma. Malignancy potential and differentiation from hepatocellular carcinoma]. Pathologe; 2006 Jul;27(4):238-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular adenoma. Malignancy potential and differentiation from hepatocellular carcinoma].
  • [Transliterated title] Leberzelladenom. Entartungspotenzial und Abgrenzung vom hepatozellulären Karzinom.
  • In contrast to hepatocellular carcinoma (HCC), very few molecular pathological studies have been carried out on hepatocellular adenoma (HCA).
  • Particularly from the surgical point of view, based on views passed on verbally and in the literature of the 1970s and 1980s, a possible degeneration of the HCA provides grounds for operating.
  • Published cases of transitions from HCA into HCC were evaluated on the basis of today's morphological standards.
  • A comparison was made between the patterns of new molecular pathological studies of HCA, above all the work of our own groups, and those of HCC.
  • The results speak against the suggestion that a typical solitary HCA in pre-menopausal women is a precursor lesion of HCC.
  • After a critical review of the literature, only one casuistic case of a transition of HCA to HCC under a hormone therapy, which is no longer practiced today, remained.
  • A limitation of particular HCA in genetic and metabolic diseases, children, adult males, adenomatosis, and HCA-like tumors with known risk factors of HCC would seem pragmatically meaningful.
  • With classic HCA, however, the oncological indication for surgery does not apply.
  • [MeSH-major] Adenoma / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):296-9 [6263214.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2379-81 [14562419.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):927-35 [12297840.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2584-8 [179705.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1211-8 [15887105.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):189-96 [11904335.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3654-60 [15897561.001]
  • [Cites] Zentralbl Chir. 1998;123(2):140-4 [9556886.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):558-64 [3190282.001]
  • [Cites] Eur J Contracept Reprod Health Care. 1998 Dec;3(4):194-200 [10036602.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):138-43 [12203777.001]
  • [Cites] J Hepatol. 2004 Jun;40(6):1036-9 [15158349.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):341-7 [1712664.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):470-5 [11950923.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):919-22 [9041254.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1858-62 [10347130.001]
  • [Cites] Radiology. 2000 Aug;216(2):395-402 [10924560.001]
  • [Cites] Pathologica. 2003 Apr;95(2):71-82 [12768875.001]
  • [Cites] Pathologe. 2001 May;22(3):184-90 [11402848.001]
  • [Cites] J Pathol. 2001 Apr;193(4):476-82 [11276006.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):68-73 [11333302.001]
  • [Cites] Am J Surg Pathol. 1993 May;17(5):525-9 [8385884.001]
  • [Cites] Histopathology. 2006 Jun;48(7):876-8 [16722942.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1113-23 [8214256.001]
  • [Cites] Eur J Pediatr. 1993;152 Suppl 1:S63-70 [8391447.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):852-5 [12203220.001]
  • [Cites] Gut. 2002 Aug;51(2):253-8 [12117890.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 1994 Jan-Feb;49(1):30-3 [8029613.001]
  • [Cites] Expert Rev Mol Diagn. 2002 Mar;2(2):120-8 [11962332.001]
  • [Cites] Hepatology. 1993 Apr;17 (4):583-5 [7682980.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1510-5 [6311396.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):547-9 [3019201.001]
  • [Cites] Arch Surg. 1994 Jul;129(7):712-7 [7517661.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):222-6 [14736278.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1033-8 [11529826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1309-14 [14745031.001]
  • [Cites] J Hepatol. 1996 Dec;25(6):976-9 [9007729.001]
  • [Cites] Histopathology. 1996 May;28(5):472-4 [8735726.001]
  • [Cites] Ann Intern Med. 1989 Mar 15;110(6):489-90 [2537593.001]
  • (PMID = 16736176.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


79. Finnell CW, Madan AK, Ternovits CA, Menachery SJ, Tichansky DS: Unexpected pathology during laparoscopic bariatric surgery. Surg Endosc; 2007 Jun;21(6):867-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The findings included lesions on the small bowel (n = 3), stomach (n = 4), and liver (n = 2).
  • The final pathology showed gastric leiomyomas (n = 2), gastric gastrointestinal stromal cell tumors (n = 2), ectopic pancreatic tissue (n = 2), arteriovenous malformation (n = 1), biliary adenoma (n = 1), and fibrosed hemangioma (n = 1).

  • MedlinePlus Health Information. consumer health - Digestive Diseases.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2003 Jul;186(1):40-4 [12842747.001]
  • [Cites] Ann Intern Med. 2005 Apr 5;142(7):547-59 [15809466.001]
  • [Cites] Obes Surg. 2001 Feb;11(1):40-5 [11361167.001]
  • [Cites] JAMA. 2004 Jun 16;291(23):2847-50 [15199035.001]
  • [Cites] Am Surg. 2004 Aug;70(8):684-6 [15328800.001]
  • [Cites] Obes Surg. 2005 Oct;15(9):1332-5 [16259898.001]
  • [Cites] Obes Surg. 1998 Jun;8(3):314 [9678200.001]
  • [Cites] Obes Surg. 2004 Oct;14(9):1216-21 [15527637.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2683-93 [15616203.001]
  • [Cites] Obes Surg. 2005 Nov-Dec;15(10):1384-8 [16354516.001]
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):149-55; discussion 155-7 [10945358.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):78-83 [11961610.001]
  • [Cites] Obes Surg. 2002 Oct;12(5):634-8 [12448383.001]
  • [Cites] Surg Obes Relat Dis. 2005 Jan-Feb;1(1):22-4 [16925197.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):279-89; discussion 289-91 [11524581.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1075-9 [15014179.001]
  • [Cites] Ann Intern Med. 1991 Dec 15;115(12):956-61 [1952493.001]
  • [Cites] J Am Coll Surg. 2001 Apr;192(4):469-76; discussion 476-7 [11294404.001]
  • [Cites] Obes Surg. 2001 Oct;11(5):570-5 [11594097.001]
  • [Cites] JAMA. 2004 Oct 13;292(14):1724-37 [15479938.001]
  • [Cites] J Am Coll Surg. 2002 May;194(5):557-66; discussion 566-7 [12022597.001]
  • [Cites] Obes Surg. 1994 Nov;4(4):353-357 [10742801.001]
  • [Cites] Obes Surg. 2004 Nov-Dec;14(10):1367-72 [15603653.001]
  • [Cites] Obes Surg. 2002 Dec;12(6):874-5 [12568199.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):909-16 [11485526.001]
  • [Cites] Obes Surg. 1997 Feb;7(1):16-8 [9730531.001]
  • (PMID = 17149553.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Waldkirch E, Uckert S, Schultheiss D, Geismar U, Bruns C, Scheller F, Jonas U, Becker AJ, Stief CG, Hedlund P: Non-genomic effects of androgens on isolated human vascular and nonvascular penile erectile tissue. BJU Int; 2008 Jan;101(1):71-5; discussion 75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate non-genomic effects of testosterone and dihydrotestosterone (DHT) on isolated human cavernosal arteries (HCA) and corpus cavernosum (HCC) using organ-bath studies and radio-immunoassays (RIA), as non-genomic effects of androgens are reported for vascular smooth musculature and there is evidence that the relaxant response involves a modulation of cyclic nucleotide tissue levels.
  • MATERIALS AND METHODS: The relaxation induced by the cumulative addition of testosterone and DHT (0.01-10 microm) was studied using circular segments of HCA and strip preparations of HCC.
  • CONCLUSION: Rapid androgen-induced relaxation of HCA and HCC occurs via non-genomic mechanisms.

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868421.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; E0399OZS9N / Cyclic AMP; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


81. Miyaki M, Yamaguchi T, Iijima T, Funata N, Mori T: Difference in the role of loss of heterozygosity at 10p15 (KLF6 locus) in colorectal carcinogenesis between sporadic and familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer patients. Oncology; 2006;71(1-2):131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: It was found that the frequencies of LOH (sum of M1 and M2) were 4% in adenomas, 0% in intramucosal carcinomas, 35% in invasive carcinomas, and 33% in liver metastases in sporadic cases.
  • Mutation analysis of the KLF6 gene in 298 colorectal tumors detected no somatic mutations.
  • [MeSH-minor] Adenoma / genetics. Humans. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational


82. Ohbayashi H, Umeda Y, Senoh H, Kasai T, Kano H, Nagano K, Arito H, Fukushima S: Enhanced hepatocarcinogenicity by combined inhalation and oral exposures to N,N-dimethylformamide in male rats. J Toxicol Sci; 2009 Feb;34(1):53-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A group of 50 male F344 rats, 6-week-old, was exposed by inhalation to 0 (clean air), 200, or 400 ppm (v/v) of DMF vapor-containing air for 6 hr/day and 5 days/week during a 104-week period, and each inhalation group was given ad libitum DMF-formulated drinking water at 0, 800 or 1,600 ppm (w/w) for 104 weeks.
  • Incidences of hepatocellular adenomas and carcinomas and their combined incidences were significantly increased in the combined-exposure groups compared with the untreated control group or each of the inhalation-alone and oral-alone groups with matching concentrations.
  • Incidences of hepatocellular adenomas and carcinomas induced by the combined exposures were greater than the sum of the two incidences of the hepatocellular adenomas and carcinomas induced by the single-route exposures through inhalation and ingestion.
  • It was concluded that the combined inhalation and oral exposures markedly enhance the incidences and malignancy of hepatocellular tumors, suggesting that the hepatocarcinogenic effect of the combined exposures is greater than the effect that would be expected under the assumption that the two effects of single-route exposures through inhalation and drinking are additive.
  • [MeSH-major] Adenoma, Liver Cell / chemically induced. Carcinogens / toxicity. Carcinoma, Hepatocellular / chemically induced. Environmental Pollutants / toxicity. Formamides / toxicity

  • Hazardous Substances Data Bank. N,N-DIMETHYLFORMAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19182435.001).
  • [ISSN] 1880-3989
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Environmental Pollutants; 0 / Formamides; 8696NH0Y2X / Dimethylformamide
  •  go-up   go-down


83. Bicknell DC, Bodmer WF: A mutated HLA-A*0101 allele in the colorectal cell line HCA-7. Tissue Antigens; 2005 Sep;66(3):231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mutated HLA-A*0101 allele in the colorectal cell line HCA-7.
  • The colorectal cell line HCA-7 expresses surface human leucocyte antigen-A*0201 (HLA-A*0201), but lacks expression of HLA-A*0101 whilst the normal B-cell line (EVA-1224), derived from the same individual, expresses both surface HLA-A1 and HLA-A2.
  • Amplification refractory mutation system-polymerase chain reaction analysis, using sequence-specific primers, suggested that HCA-7 has a mutation in a 7 base pair (bp) cytosine repeat sequence located at the beginning of Exon 4 (bp 621-627).
  • Cloning and sequencing revealed HCA-7 to have eight cytosine residues in this repeat sequence.
  • Analysis of the mRNA for HLA-A*010 using reverse trancriptase-polymerase chain reaction (RT-PCR), with an allele-specific 5' primer in exon 2 (bp 253-271) and a series of 3' primers in exons 3, 4 and 7 and in the 3'untranslated region, revealed that HCA-7 contained a shortened message terminating in the region of the exon 3/4 boundary.
  • HCA-7 is mismatch repair (MMR) defective due to lack of expression of hMLH1 resulting from hypermethylation of the promoter region.
  • [MeSH-minor] 3' Untranslated Regions. Alleles. Base Pair Mismatch. Cell Line, Tumor. Cloning, Molecular. Cytosine. DNA / metabolism. DNA Primers / genetics. DNA Repair. Exons. Gene Frequency. HLA-A1 Antigen. HLA-A2 Antigen. Humans. Isoelectric Focusing. Polymerase Chain Reaction. Promoter Regions, Genetic. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101834.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / DNA Primers; 0 / HLA-A Antigens; 0 / HLA-A*01:01 antigen; 0 / HLA-A*02:01 antigen; 0 / HLA-A1 Antigen; 0 / HLA-A2 Antigen; 63231-63-0 / RNA; 8J337D1HZY / Cytosine; 9007-49-2 / DNA
  •  go-up   go-down


84. Galloro V: HCA initiates Texas two-step. Allegations spur Baylor joint-venture investigations. Mod Healthc; 2006 May 15;36(20):8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA initiates Texas two-step. Allegations spur Baylor joint-venture investigations.

  • MedlinePlus Health Information. consumer health - Health Fraud.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752858.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] Legal Cases; News
  • [Publication-country] United States
  •  go-up   go-down


85. Galloro V: LifePoint rethinks HCA deal. Renegotiations are under way for five hospitals. Mod Healthc; 2006 Apr 10;36(15):8-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LifePoint rethinks HCA deal. Renegotiations are under way for five hospitals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671188.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


86. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, Rikkers LF, Weber SM: Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg; 2006 Oct;141(10):1000-4; discussion 1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic neuroendocrine hepatic tumors: resection improves survival.
  • BACKGROUND: The optimal treatment for hepatic metastases from neuroendocrine tumors remains controversial because of the often indolent nature of these tumors.
  • We sought to determine the effect of 3 major treatment modalities including medical therapy, hepatic artery embolization, and surgical resection, ablation, or both in patients with liver-only neuroendocrine metastases, with the hypothesis that surgical treatment is associated with improvement in survival.
  • PATIENTS: Patients with metastatic liver-only neuroendocrine tumors were identified from hospital records.
  • INTERVENTIONS: Patients were subdivided into those receiving medical therapy, hepatic artery embolization, or surgical management.
  • RESULTS: From January 1996 through May 2004, 48 patients with liver-only neuroendocrine metastases were identified (median follow-up, 20 months), including 36 carcinoid and 12 islet cell tumors.
  • Hepatic artery embolization was performed in 18 patients.
  • Thirteen patients underwent surgical therapy, including anatomical liver resection (n = 6), ablation (n = 4), or combined resection and ablation (n = 3).
  • No difference was noted in the percentage of liver involved with tumor between the 3 groups.
  • CONCLUSION: In patients with liver-only neuroendocrine metastases, surgical therapy using resection, ablation, or both is associated with improved survival.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / therapy. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Catheter Ablation. Disease-Free Survival. Embolization, Therapeutic. Female. Hepatectomy. Hepatic Artery. Humans. Male. Octreotide / therapeutic use. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043278.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


87. Shirley Law. Nurs Older People; 2009 Mar 11;21(2):16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Shirley is currently seconded to the Dementia Services Development Centre (DSDC) at the University of Stirling where she is project manager for an innovative RCN-accredited study programme for healthcare assistants (HCAs) working in hospitals and care homes.
  • By the end of its first year, 800 HCAs had undertaken the programme throughout the UK.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27745086.001).
  • [ISSN] 1472-0795
  • [Journal-full-title] Nursing older people
  • [ISO-abbreviation] Nurs Older People
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Becker C: HCA's private ambitions. What twists could the industry expect this time? Mod Healthc; 2006 Jul 31;36(30):8-9, 16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA's private ambitions. What twists could the industry expect this time?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913009.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


89. Trainer PJ: ACROSTUDY: the first 5 years. Eur J Endocrinol; 2009 Nov;161 Suppl 1:S19-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The AEs most frequently attributed to pegvisomant were disturbed liver function tests and injection site reactions.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684052.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Hemoglobin A, Glycosylated; 0 / Hormone Antagonists; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


90. Inoue K, Shibutani M, Masutomi N, Toyoda K, Takagi H, Takahashi M, Fujimoto H, Hirose M, Nishikawa A: One-year chronic toxicity of madder color in F344 rats--induction of preneoplastic/neoplastic lesions in the kidney and liver. Food Chem Toxicol; 2008 Oct;46(10):3303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-year chronic toxicity of madder color in F344 rats--induction of preneoplastic/neoplastic lesions in the kidney and liver.
  • Relative weights of the liver were significantly increased from 1.0% in both sexes, and those of the kidney were significantly increased from 1.0% in males and from 0.2% in females.
  • Histopathologically, atypical renal tubule hyperplasias were increased at 1.0% or higher in both sexes in association with increase of cell proliferative activity in the tubules.
  • A renal cell adenoma was observed in a male rat receiving 5.0% MC.
  • In addition, glutathione S-transferase placental form-positive liver cell foci were significantly increased at 5.0% in both sexes.
  • These results indicate that MC has chronic toxicity targeting kidney, liver and blood cells.
  • Moreover, the results strongly suggest that MC may have the carcinogenic potential in the kidney and the liver.
  • [MeSH-major] Kidney Neoplasms / chemically induced. Liver Neoplasms / chemically induced. Plant Extracts / administration & dosage. Plant Extracts / toxicity. Precancerous Conditions / chemically induced. Rubia / toxicity
  • [MeSH-minor] Animals. Cell Proliferation. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Kidney / cytology. Male. Rats. Rats, Inbred F344. Toxicity Tests, Chronic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723070.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / madder color
  •  go-up   go-down


91. Ueda Y: What is the best method for brain protection in surgery of the aortic arch? Retrograde cerebral perfusion. Cardiol Clin; 2010 May;28(2):371-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The technical simplicity of retrograde cerebral perfusion (RCP) together with a highly favorable effect upon stroke rates and survival after aortic arch surgery justifies continued clinical use of RCP in patients requiring hypothermic circulatory arrest (HCA), in particular patients with dissecting or atheromatous arch branches.
  • In clinical practice, using RCP can provide effective brain protection in HCA for about 40 to 60 minutes, although there is a time limitation.
  • [MeSH-major] Aorta, Thoracic / surgery. Aortic Aneurysm, Thoracic / surgery. Cerebrovascular Circulation / physiology. Circulatory Arrest, Deep Hypothermia Induced / adverse effects. Perfusion / methods. Stroke / prevention & control. Vascular Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Cardiol Clin. 2010 May;28(2):403-4 [20452559.001]
  • (PMID = 20452556.001).
  • [ISSN] 1558-2264
  • [Journal-full-title] Cardiology clinics
  • [ISO-abbreviation] Cardiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 39
  •  go-up   go-down


92. Choi YD, Kim KS, Ryu S, Park Y, Cho NH, Rha SH, Jang JJ, Ro JY, Juhng SW, Choi C: Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci; 2007 Apr;22(2):305-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma.
  • We examined the immunohistochemical expression of claudin-7 and parvalbumin in 239 renal tumors, including 179 clear cell renal cell carcinoma (RCC)s, 29 papillary RCCs, 20 chromophobe RCCs, and 11 renal oncocytomas.
  • Claudin-7 and parvalbumin immunostains were positive in 3.4%, 7.8% of clear cell RCCs, 34.5%, 31.0% of papillary RCCs, 95.0%, 80.0% of chromophobe RCCs, and 72.7%, 81.8% of renal oncocytomas, respectively.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Claudins. Humans. Neoplasm Proteins / metabolism. Nephrons / metabolism. Reproducibility of Results. Sensitivity and Specificity. Tissue Distribution. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):922-30 [9255255.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):760-7 [11504835.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):154-8 [12089725.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):992-3 [9307205.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):419-24 [9537468.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):310-7 [10102617.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):268-73 [10370242.001]
  • [Cites] J Urol. 1999 Oct;162(4):1246-58 [10492174.001]
  • [Cites] Histopathology. 2004 Dec;45(6):593-602 [15569050.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):712-7 [12118108.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):199-205 [12548166.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] J Membr Biol. 2003 Aug 1;194(3):187-97 [14502431.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Oncogene. 2004 Jun 3;23(26):4646-54 [15064707.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] J Biol Chem. 1987 Jun 25;262(18):8696-701 [3036821.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):237-45 [2565618.001]
  • [Cites] Mod Pathol. 1993 Jul;6(4):449-56 [8415591.001]
  • [Cites] J Urol. 1995 Sep;154(3):964-7 [7637102.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):124-37 [10768592.001]
  • (PMID = 17449941.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2693599
  •  go-up   go-down


93. Ao L, Liu JY, Liu WB, Gao LH, Hu R, Fang ZJ, Zhen ZX, Huang MH, Yang MS, Cao J: Comparison of gene expression profiles in BALB/c 3T3 transformed foci exposed to tumor promoting agents. Toxicol In Vitro; 2010 Mar;24(2):430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, cDNA microarrays were used to analyze gene expression and discern chemical-associated profiles induced by a variety of tumor promoting agents in transformed cells.
  • Two-stage transformation model of BALB/c 3T3 cells was established with MNNG as initiator, and 12-O-tetradecanoylphorbol-13-acetate (TPA), okadaic acid (OA), or cadmium chloride (CdCl(2)) as tumor promoters.
  • Nine morphologically transformed foci were isolated and the anchorage-independent growth of transformed cells was verified.
  • Unsupervised hierarchical clustering analysis revealed that the nine foci were classified into three groups in concordance with the promoters used to induce them and characteristic clusters of genes were identified.
  • Moreover, common gene expression alterations were also observed in foci, including upregulated genes associated with cell proliferation and downregulated genes associated with extracellular matrix.
  • Our results demonstrate the presence of unique gene expression profiles in transformed cells which reflect the etiological chemicals and indicate the importance of characteristic molecular alterations as potential biomarkers of exposure to tumor promoters.
  • [MeSH-minor] Animals. BALB 3T3 Cells. Cell Proliferation / drug effects. Extracellular Matrix. Mice. Protein Array Analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. CADMIUM CHLORIDE .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. OKADAIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19840844.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 1W21G5Q4N2 / Okadaic Acid; J6K4F9V3BA / Cadmium Chloride; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


94. Yan BC, Hart JA: Recent developments in liver pathology. Arch Pathol Lab Med; 2009 Jul;133(7):1078-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in liver pathology.
  • CONTEXT: Hepatocellular carcinoma is the sixth most common malignancy and the third leading cause of cancer deaths worldwide, making pathologic identification of precursor lesions essential.
  • Recent molecular genetic, pathologic, and clinical data have led to the stratification of hepatic adenomas into subgroups with unique molecular profiles and varying potential for malignant transformation, as well as to the reclassification of telangiectatic focal nodular hyperplasia as telangiectatic adenoma.
  • Clinical, morphologic, and molecular genetic studies have also established juvenile hemochromatosis and pediatric nonalcoholic steatohepatitis as entities distinct from their adult counterparts.
  • OBJECTIVE: To review the recent molecular genetic characterization of telangiectatic hepatic adenomas and juvenile hemochromatosis, as well as the recent clinicopathologic characterization of pediatric nonalcoholic steatohepatitis.
  • CONCLUSIONS: Basic science and translational research have led to the classification of many pathologic entities of the liver according to molecular genetic and protein expression profiles that correspond to traditional morphologic categories.
  • Insights into signal transduction pathways that are activated in, and protein expression patterns unique to, an individual disease may lead to the development of new therapeutic agents and novel diagnostic biomarkers.
  • [MeSH-major] Fatty Liver / pathology. Hemochromatosis / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / genetics. Adenoma / pathology. Adolescent. Adult. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / epidemiology. Child. Child, Preschool. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Hemochromatosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642734.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 119
  •  go-up   go-down


95. Jones DH, Silberstein PT, Lynch H, Ternet C: Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis. J Clin Oncol; 2005 Sep 1;23(25):6278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


96. Kim YS, Rha SE, Oh SN, Jung SE, Shin YR, Choi BG, Byun JY, Jung ES, Kim DG: Imaging findings of intrahepatic bile duct adenoma (peribiliary gland hamartoma): a case report and literature review. Korean J Radiol; 2010 Sep-Oct;11(5):560-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings of intrahepatic bile duct adenoma (peribiliary gland hamartoma): a case report and literature review.
  • Intrahepatic bile duct adenoma is a rare benign epithelial hepatic tumor derived from bile duct cells.
  • We report the imaging findings of a patient with bile duct adenoma, which appeared as a small heterogeneously enhancing mass with focal small cystic change on CT and MRI.
  • Although rare, bile duct adenoma should be considered as a differential diagnosis of a small hypervascular tumor located in the periphery of liver.
  • [MeSH-major] Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Hamartoma / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bile duct adenoma .
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for intrahepatic bile duct adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ulster Med J. 1999 Nov;68(2):114-5 [10661642.001]
  • [Cites] Am Surg. 1975 Feb;41(2):106-8 [1122059.001]
  • [Cites] Arch Surg. 1978 Mar;113(3):272-4 [205188.001]
  • [Cites] Arch Pathol Lab Med. 1984 Nov;108(11):922-4 [6548370.001]
  • [Cites] Am J Surg Pathol. 1988 Sep;12(9):708-15 [3046396.001]
  • [Cites] Radiographics. 2009 Oct;29(6):1725-48 [19959518.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):858-64 [8669534.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):196-201 [10441025.001]
  • [Cites] J Comput Assist Tomogr. 1999 Sep-Oct;23(5):690-5 [10524847.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):381-9 [15725808.001]
  • [Cites] Radiat Med. 2006 Jul;24(6):459-62 [16958429.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17(3):397-402 [8388005.001]
  • (PMID = 20808701.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2930166
  • [Keywords] NOTNLM ; Adenoma / Bile duct / Computed tomography (CT) / Liver / Magnetic resonance (MR)
  •  go-up   go-down


97. Rao S, Patel A, Levin K, Lu M, Garbarino K, Myers D, Walker EM, Ryu S, Ho Kim J, Movsas B: How often are previously undetected radiographic abnormalities detected at the time of CT simulation for breast cancer patients? Am J Clin Oncol; 2010 Jun;33(3):262-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this analysis was to determine the percentage of cases in which a previously undetected radiographic finding was found on review of CT simulation images by diagnostic radiology.
  • The percentage of these reports in which a previously undetected abnormality was noted on the planning CT was determined.
  • RESULTS: Of 332 patients with CT simulations for breast cancer treatment planning, 52 patients (16%) had a newly detected abnormality noted.
  • Of these, 31 patients (or 60% of the abnormal findings) were deemed by diagnostic radiology to have potentially significant findings (e.g., "can not exclude metastatic disease"), and a follow-up CT or magnetic resonance imaging scan was recommended.
  • Abnormalities in this category included previously undetected lung nodules, liver lesions, kidney/adrenal lesions, and sclerotic bony lesions.
  • [MeSH-minor] Adenoma / radiography. Adrenal Gland Neoplasms / radiography. Adrenal Glands / radiography. Aged. Bone and Bones / radiography. Cysts / radiography. False Negative Reactions. Female. Granuloma / radiography. Heart Neoplasms / radiography. Humans. Kidney / radiography. Liver / radiography. Lung / radiography. Mediastinum / radiography. Middle Aged. Multiple Pulmonary Nodules / radiography. Myxoma / radiography. Thyroid Diseases / radiography

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823073.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Wang D, Lagerstrom R, Sun C, Bishof L, Valotton P, Götte M: HCA-vision: Automated neurite outgrowth analysis. J Biomol Screen; 2010 Oct;15(9):1165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA-vision: Automated neurite outgrowth analysis.
  • Automating the analysis of neurons in culture represents a key aspect of the search for neuroactive compounds.
  • A number of commercial neurite analysis software packages tend to measure some basic features such as total neurite length and number of branching points.
  • The authors have developed a suite of image analysis tools that will allow researchers to produce quality analyses at primary screening rates.
  • In mixed cell populations, neurons can be filtered and separated from other brain cell types so that neurite analysis can be performed only on neurons.
  • It supports batch processing with a built-in database to store the batch-processing results, a batch result viewer, and an ad hoc query builder for users to retrieve features of interest.
  • The suite of tools has been deployed into a software package called HCA-Vision.
  • The free version of the software package is available at http://www.hca-vision.com.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855562.001).
  • [ISSN] 1552-454X
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor
  •  go-up   go-down


99. Güzel O, Innocenti A, Hall RA, Scozzafava A, Mühlschlegel FA, Supuran CT: Carbonic anhydrase inhibitors. The nematode alpha-carbonic anhydrase of Caenorhabditis elegans CAH-4b is highly inhibited by 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. Bioorg Med Chem; 2009 Apr 15;17(8):3212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of these sulfonamides also showed a good selectivity profile for the inhibition of the nematode over the human isozymes CA I and II (selectivity ratios in the range of 1.78-4.95 for the inhibition of ceCA over hCA II).

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201197.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601049; United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Hydrazines; 0 / Indoles; 0 / Isoenzymes; 0 / Sulfonamides; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


100. Lee BH, Seong J, Kim UJ, Won R, Kim J: Behavioral characteristics of a mouse model of cancer pain. Yonsei Med J; 2005 Apr 30;46(2):252-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Murine hepatocarcinoma cells, HCa-1, were inoculated unilaterally into the thigh or the dorsum of the foot of male C3H/HeJ mice.
  • Bone invasion by the tumor commenced from 7 days after inoculation of tumor cells and was evident from 14 days after inoculation.
  • These results suggest that carcinoma cells injected into the foot of mice may develop severe chronic pain related to cancer.
  • [MeSH-minor] Animals. Bone and Bones / pathology. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cold Temperature. Disease Models, Animal. Foot. Liver Neoplasms / pathology. Male. Mice. Mice, Inbred C3H. Neoplasm Invasiveness. Neoplasm Transplantation. Pain Threshold. Physical Stimulation. Thigh

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1990 Feb 5;508(2):329-32 [2306625.001]
  • [Cites] Cancer Res. 1974 Jan;34(1):61-71 [4809463.001]
  • [Cites] Pain. 1990 Nov;43(2):205-18 [1982347.001]
  • [Cites] Exp Brain Res. 1993;92(3):441-52 [8454008.001]
  • [Cites] Pain. 1993 Nov;55(2):267-73 [8309714.001]
  • [Cites] J Neurosci. 1994 May;14(5 Pt 1):2708-23 [8182437.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1695-700 [10335806.001]
  • [Cites] Pain. 1999 Apr;80(3):521-31 [10342413.001]
  • [Cites] Pain. 1999 Sep;82(3):263-74 [10488677.001]
  • [Cites] J Neurosci. 2001 Dec 1;21(23):9355-66 [11717369.001]
  • [Cites] J Neurosci. 2001 Dec 1;21(23):9367-76 [11717370.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Neuroreport. 2000 Mar 20;11(4):657-61 [10757496.001]
  • [Cites] Neuroscience. 2000;98(3):585-98 [10869852.001]
  • [Cites] Yonsei Med J. 2000 Jun;41(3):354-61 [10957890.001]
  • [Cites] Yonsei Med J. 2001 Feb;42(1):30-40 [11293499.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4038-47 [11358823.001]
  • [Cites] Pain. 2002 Mar;96(1-2):129-40 [11932069.001]
  • [Cites] Yonsei Med J. 2002 Jun;43(3):370-6 [12089747.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):550-8 [12594809.001]
  • [Cites] Pain. 1990 May;41(2):235-51 [2164179.001]
  • (PMID = 15861499.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2823022
  •  go-up   go-down






Advertisement